

Washington University

Report on Federal Financial Assistance

Programs in Accordance with Uniform Guidance

For the Year Ended June 30, 2024

Employer Identification Number: 43-0653611

Washington University
Report on Federal Financial Assistance Programs in
Accordance with Uniform Guidance
Index
June 30, 2024

	Page(s)
A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION	
Report of Independent Auditors	1–3
Consolidated Financial Statements for the Years Ended June 30, 2024 and 2023.....	4–34
Schedule of Expenditures of Federal Awards	35–52
Notes to Schedule of Expenditures of Federal Awards	53
B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	54–55
Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance	56–58
C. SCHEDULE OF FINDINGS AND QUESTIONED COSTS	
Part I – Summary of Auditors’ Results	59
Part II – Financial Statement Findings	60
Part III – Federal Award Findings and Questioned Costs	60–63
Part IV – Summary of Status of Prior Audit Findings	64
Management's Views and Corrective Action Plan	65–67

Financial Statements and Supplemental Information



Report of Independent Auditors

To the Board of Trustees of Washington University

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statements of financial position as of June 30, 2024 and 2023, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of June 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from



fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2024 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.



Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated September 27, 2024 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2024. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the University's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Washington, District of Columbia

September 27, 2024

Washington University
Consolidated Statements of Financial Position
June 30, 2024 and 2023

(thousands of dollars)

	2024	2023
Assets		
Cash and cash equivalents	\$ 230,474	\$ 316,820
Investments	14,697,939	14,311,571
Accounts and notes receivable, net	836,930	723,215
Pledges receivable, net	405,133	418,821
Right-of-use assets	88,882	93,447
Other assets	433,132	362,291
Fixed assets, net	<u>3,794,317</u>	<u>3,566,162</u>
Total assets	<u>\$ 20,486,807</u>	<u>\$ 19,792,327</u>
Liabilities		
Accounts payable and accrued expenses	\$ 741,620	\$ 731,057
Deposits, advances and other	35,654	48,541
Lease liability	98,715	104,087
Professional liability	113,686	104,012
Deferred revenue and contract liabilities	141,837	124,803
Liabilities under split-interest agreements	33,691	34,607
Notes and bonds payable	<u>3,266,308</u>	<u>3,259,475</u>
Total liabilities	<u>4,431,511</u>	<u>4,406,582</u>
Net Assets		
Without donor restrictions	8,004,693	7,693,793
With donor restrictions	<u>8,050,603</u>	<u>7,691,952</u>
Total net assets	<u>16,055,296</u>	<u>15,385,745</u>
Total liabilities and net assets	<u>\$ 20,486,807</u>	<u>\$ 19,792,327</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
Year Ended June 30, 2024

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 479,327	\$ -	\$ 479,327
Endowment spending distribution	553,240	22,705	575,945
Investment income	94,241	777	95,018
Gifts	107,570	139,686	247,256
Grants and contracts revenues			
Direct costs recovered	671,148	-	671,148
Facilities and administrative costs recovered	256,425	-	256,425
Patient services, net	2,359,708	-	2,359,708
Auxiliary enterprises - sales and services	142,534	-	142,534
Educational activities - sales and services	170,455	-	170,455
Affiliated hospital revenues	189,804	-	189,804
Other revenue	45,854	2	45,856
Net assets released from restrictions	140,290	(140,290)	-
Total revenues and other support	<u>5,210,596</u>	<u>22,880</u>	<u>5,233,476</u>
Expenses			
Compensation expense	3,079,115	-	3,079,115
Supplies, services, and other	1,643,736	-	1,643,736
Depreciation expense	255,521	-	255,521
Interest expense	104,787	-	104,787
Total expenses	<u>5,083,159</u>	<u>-</u>	<u>5,083,159</u>
Net operating results	<u>127,437</u>	<u>22,880</u>	<u>150,317</u>
Non-operating activities			
Investment returns net of endowment spending	210,616	236,330	446,946
Permanently restricted gifts	-	78,708	78,708
Other non-operating	(27,153)	20,733	(6,420)
Non-operating, net	<u>183,463</u>	<u>335,771</u>	<u>519,234</u>
Change in net assets	310,900	358,651	669,551
Net Assets, Beginning of the Year	<u>7,693,793</u>	<u>7,691,952</u>	<u>15,385,745</u>
Net Assets, End of the Year	<u>\$ 8,004,693</u>	<u>\$ 8,050,603</u>	<u>\$ 16,055,296</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
Year Ended June 30, 2023

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 497,365	\$ -	\$ 497,365
Endowment spending distribution	552,477	17,312	569,789
Investment income	71,397	837	72,234
Gifts	110,294	93,854	204,148
Grants and contracts revenues			
Direct costs recovered	617,177	-	617,177
Facilities and administrative costs recovered	235,870	-	235,870
Patient services, net	2,052,095	-	2,052,095
Auxiliary enterprises - sales and services	137,124	-	137,124
Educational activities - sales and services	168,263	-	168,263
Affiliated hospital revenues	164,808	-	164,808
Other revenue	38,130	-	38,130
Net assets released from restrictions	122,374	(122,374)	-
Total revenues and other support	<u>4,767,374</u>	<u>(10,371)</u>	<u>4,757,003</u>
Expenses			
Compensation expense	2,770,311	-	2,770,311
Supplies, services, and other	1,481,509	-	1,481,509
Depreciation expense	224,969	-	224,969
Interest expense	93,738	-	93,738
Total expenses	<u>4,570,527</u>	<u>-</u>	<u>4,570,527</u>
Net operating results	<u>196,847</u>	<u>(10,371)</u>	<u>186,476</u>
Non-operating activities			
Investment returns net of endowment spending	(343,688)	(593,435)	(937,123)
Permanently restricted gifts	-	88,345	88,345
Other non-operating	(6,454)	10,047	3,593
Non-operating, net	<u>(350,142)</u>	<u>(495,043)</u>	<u>(845,185)</u>
Change in net assets	(153,295)	(505,414)	(658,709)
Net Assets, Beginning of the Year	7,847,088	8,197,366	16,044,454
Net Assets, End of the Year	<u>\$ 7,693,793</u>	<u>\$ 7,691,952</u>	<u>\$ 15,385,745</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University

Consolidated Statements of Cash Flows

Years Ended June 30, 2024 and 2023

(thousands of dollars)

	2024	2023
Cash flows from operating activities		
Change in net assets	\$ 669,551	\$ (658,709)
Adjustments to reconcile change in net assets to cash used in operating activities		
Realized and unrealized net (gains) and losses on investments	(1,073,305)	313,738
Depreciation expense	255,521	224,969
Permanently restricted gifts	(78,708)	(88,345)
Investments received as gifts - not permanently restricted	(38,204)	(5,193)
Proceeds from sales of investments received as gifts	38,204	5,193
Other non-cash adjustments	3,440	39,135
Changes in assets and liabilities		
Accounts and notes receivable, net	(98,487)	15,183
Pledges receivable, net	11,008	1,668
Accounts payable and accrued expenses	(14,710)	24,374
Deferred revenue and contract liabilities	17,034	(5,677)
Lease liabilities	(23,753)	(22,635)
Other assets and liabilities	(31,869)	(41,611)
Net cash used by operating activities	(364,278)	(197,910)
Cash flows from investing activities		
Proceeds from sales and maturities of investments	4,048,801	7,625,584
Purchases of investments	(3,350,448)	(6,831,465)
Purchases of fixed assets	(510,219)	(543,043)
Student loans disbursed	(16,189)	(16,987)
Student loan payments received	14,609	15,956
Other	(22)	(288)
Net cash provided by investing activities	186,532	249,757
Cash flows from financing activities		
Principal payments of debt	(2,577)	(79,942)
Proceeds from long-term debt issuance	8,930	14,340
Contributions restricted for long-term investment	72,117	67,097
Proceeds from sales of investments received as permanently restricted gifts	12,930	24,287
Net cash provided by financing activities	91,400	25,782
Net (decrease)/increase in cash and cash equivalents	(86,346)	77,629
Cash and cash equivalents		
Beginning of year	316,820	239,191
End of year	\$ 230,474	\$ 316,820
Supplemental data		
Interest paid in cash	\$ 103,379	\$ 92,785
Noncash activities		
Contributions of securities and other noncash assets	(51,134)	(29,480)
Right-of-use assets obtained in exchange for lease liabilities	(20,805)	(26,921)
Net change in accounts payable for fixed assets	(16,889)	19,644
Net change in accounts receivable for investments	(14,096)	(16,197)
Net change in accounts payable for investments	4,287	14,530

The accompanying notes are an integral part of these consolidated financial statements.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

1. Summary of Significant Accounting Policies

Organization

Washington University in St. Louis (the “university”) is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

Basis of Presentation and Use of Estimates

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates. Significant consolidated affiliates include The Barnard Free Skin and Cancer Hospital, Quadrangle Management Company, Parallel Properties LLC including its affiliates, Washington University Clinical Associates, LLC and associated physician practices, and Washington University Physicians in Illinois, Inc.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for contractual adjustments and doubtful accounts. Actual results could differ from those estimates.

Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 financial statement presentation. These reclassifications had no effect on changes in net assets.

Net Assets

Resources are recorded based on the absence or existence of donor-imposed restrictions. Descriptions of the net asset categories are as follows:

- Net assets without donor restrictions are free of donor-imposed restrictions. Board-designated endowment funds are also included within net assets without donor restrictions.
- Net assets with donor restrictions represent net assets that consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time as well as gifts and trusts which, by donor restriction, are required to be held in perpetuity. Net assets required to be held in perpetuity at June 30, 2024 and 2023, are \$2,725,313 and \$2,638,879, respectively.

Revenues from sources other than contributions and investment returns are reported as increases in net assets without donor restrictions. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose donor

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

restrictions that are met in the same fiscal year they are received are included in revenues without donor restrictions. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted endowments. Such amounts, reported in the non-operating section of the consolidated statement of activities, remain in net assets with donor restrictions until appropriated for expenditure. When a donor restriction expires due to the passage of time or the university's fulfillment of donor stipulated purpose, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions. Donor restricted gifts that are to be held in perpetuity are reported in the non-operating section of the consolidated statements of activities. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in net assets without donor restrictions.

The university's net assets as of June 30, 2024 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$ -	\$ 6,991,404	\$ 6,991,404
Board-designated endowment funds	4,439,294	575,328	5,014,622
Investment in plant, net	848,876	-	848,876
Pledges	-	405,133	405,133
Other donor-restricted	-	78,738	78,738
Operating and other reserves	<u>2,716,523</u>	<u>-</u>	<u>2,716,523</u>
	<u>\$ 8,004,693</u>	<u>\$ 8,050,603</u>	<u>\$ 16,055,296</u>

The university's net assets as of June 30, 2023 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$ -	\$ 6,686,908	\$ 6,686,908
Board-designated endowment funds	4,279,133	523,273	4,802,406
Investment in plant, net	884,026	-	884,026
Pledges	-	418,821	418,821
Other donor-restricted	-	62,950	62,950
Operating and other reserves	<u>2,530,634</u>	<u>-</u>	<u>2,530,634</u>
	<u>\$ 7,693,793</u>	<u>\$ 7,691,952</u>	<u>\$ 15,385,745</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

Cash and Cash Equivalents

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as short-term investments, to be cash and cash equivalents.

Investments

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the consolidated statements of activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

At June 30, 2024 and 2023, investments include \$320,867 and \$577,339, respectively, purchased with unexpended proceeds from the Series 2020A Missouri Health and Educational Facilities Authority (MOHEFA) taxable revenue bonds issued April 3, 2020 and the Series 2022 taxable bonds issued April 7, 2022. The 2020A MOHEFA funds and the 2022 bond funds may be utilized for the purposes set forth in the relevant bond documents.

Financing Receivables

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins Student Loan program. Loan funds are reported at estimated realizable value, which approximates fair value. Federal funds are ultimately refundable to the government and are recognized as a liability in the consolidated statements of financial position.

The university's loan portfolio includes over 3,400 individual loans and is geographically diverse. Loans are considered past due if the minimum payment is not received within ten days past the due date. At June 30, 2024 and 2023, respectively 93% and 94% of the parent loans and 78% and 76% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

Other Assets

Other assets primarily consist of prepaid expenses, deposits, inventories, and deferred compensation. The university offers deferred compensation plans for eligible faculty and staff. The plans investments are recorded at market value in other assets with an offsetting liability recorded in accounts payable and accrued expenses within the consolidated statement of financial position.

Leases

The university determines if an arrangement is or contains a lease at inception based on whether the contract conveys the right to control the use of identified property, plant, or equipment in exchange for consideration. The university has both leases under which it is obligated as a lessee and leases for which it is the lessor. Operating leases in which the university is a lessee are included in right-of-use (ROU) assets and lease liabilities on the consolidated statements of financial position. The university has elected the short-term lease exception under ASC 842 for all leases, and therefore, leases with an initial term of 12 months

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

or less are not included on the consolidated statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The interest rate implicit in lease contracts is typically not readily determinable, and as such, the university uses its collateralized borrowing rate using a period comparable with the lease term in determining the present value of lease payments. The lease term may, at the university's discretion, include options to extend or to terminate the lease that the university is reasonably certain to exercise. Lease expense for lease payments is recognized on a straight-line basis over the lease term within the supplies, services and other line of the consolidated statement of activities. Variable lease payments based on an index or rate, such as the consumer price index, are initially measured using the index or rate in effect at lease commencement. The university has lease agreements with non-lease components that relate to the lease components. The university elected the practical expedient to account for non-lease components and the lease components to which they relate as a single lease component for all leases. Leasing arrangements for which the university is the lessor are not material to the consolidated financial statements.

Fixed Assets

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation. Depreciation is calculated using the straight-line method with estimated useful lives of 10-to-50 years for buildings and building improvements, and 3-to-20 years for equipment, depending upon asset class. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Fixed assets by classification at June 30, 2024 and 2023 consist of the following:

	2024	2023
Construction in progress	\$ 605,303	\$ 911,778
Land and improvements to land	245,591	219,694
Buildings	5,635,423	4,944,844
Equipment	<u>857,756</u>	<u>820,403</u>
Total cost	7,344,073	6,896,719
Accumulated depreciation	<u>(3,549,756)</u>	<u>(3,330,557)</u>
Total fixed assets, net	<u>\$ 3,794,317</u>	<u>\$ 3,566,162</u>

Collections

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. Proceeds from the sale of deaccessioned items are used to acquire new collections. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

Deferred Revenue and Contract Liabilities

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are grants and contracts and prepaid tuition and housing.

Split-Interest Agreements

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is the standard IRS discount rate in existence at the date of the gift. The rates used range from 4.6% to 5.8% for 2024 and 1.4% to 5.0% for fiscal year 2023. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries.

Tuition and Fees

Tuition and fee revenue, net of scholarships and other implicit price concessions, is recognized over-time using the output method of measuring progress in the fiscal year in which the educational programs are conducted. Students are invoiced at the commencement of each academic period. Payment is due when invoiced. The performance obligation, delivery of educational services, is satisfied as services are rendered. If delivery of the performance obligation is not complete as of fiscal year-end, a contractual liability is recorded. The deferred contract liability at June 30, 2024 and 2023 was \$40,535 and \$43,286, respectively, and is reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to students by the university, including aid provided to employees and their dependents, for the years ended June 30, 2024 and 2023, respectively, was \$507,861 and \$477,070.

The table below identifies student aid by type. Scholarships are reported net against tuition in the consolidated statements of activities. Other amounts are reported as expenses.

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

	2024	2023
Scholarships from unrestricted sources	\$ 250,253	\$ 239,871
Scholarship support from gifts, endowment and other restricted sources	<u>122,681</u>	<u>102,799</u>
Total scholarships	372,934	342,670
Employee and dependent tuition benefits	45,447	41,643
Stipends	87,718	91,212
Work study	<u>1,762</u>	<u>1,545</u>
Total	<u>\$ 507,861</u>	<u>\$ 477,070</u>

Gifts

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax-exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.56% to 3.49%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors.

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

A summary of pledges receivable is as follows:

	2024	2023
In one year or less	\$ 167,622	\$ 176,583
Between two and five years	133,429	158,483
Over five years	<u>128,394</u>	<u>103,681</u>
	429,445	438,747
Less:		
Discount	(19,971)	(11,926)
Allowance for uncollectible amounts	<u>(4,341)</u>	<u>(8,000)</u>
Total	<u>\$ 405,133</u>	<u>\$ 418,821</u>

Grants and Contracts

The university receives grant and contract revenue from governmental and private sources. The vast majority of such agreements are awarded to the university by government agencies and are considered conditional contributions. The principle condition attached to these awards is that the university must incur costs in accordance with the Office of Management and Budget's uniform guidance before costs can be reimbursed. The university generally recognizes revenue without donor restrictions as the related costs are incurred. These revenues include recoveries of indirect costs, also referred to as facilities and administrative costs, which is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of federally sponsored programs is at rates negotiated with the Department of Health and Human Services. In some cases, the sponsor will prepay amounts in anticipation of costs to be incurred. In those cases, amounts received in excess of costs incurred are recorded as deferred revenue.

The university's current population of federal grants and contracts have an average award range of 3 – 5 years. There is no assurance that government sponsored research awards will continue to be made at current levels as awards are subject to the availability of and annual appropriation of funds. The university estimates that the total amounts promised under these agreements for which conditions have not yet been fulfilled as of June 30, 2024 and 2023, approximate or exceed current annual grants and contracts activity.

Patient Services Revenue

Net patient services revenue is reported at the amount that reflects the consideration to which the university expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including health insurers and government programs), and others. Generally, the university bills the patient and third-party payers several days after the services are performed. Revenue is recognized as performance obligations are satisfied.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges which provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

satisfy the obligation. Amounts receivable under physician service contracts with affiliated and unaffiliated hospitals are \$149,341 and \$72,943 at June 30, 2024 and 2023, respectively.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, the university has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

Generally, patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The university also provides services to uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. The university determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The university determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as there are a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. The effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Contractual adjustments to patient service revenue were \$2,903,000 and \$2,680,000 for the years ended June 30, 2024 and 2023, respectively.

The university has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. In certain instances, the university may enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The university reported patient receivables net of contractual adjustments of \$201,430 and \$151,641, at June 30, 2024 and 2023, respectively.

Auxiliary Enterprises – Sales and Services

Auxiliary enterprises sales and services revenue is primarily earned over-time utilizing the output method of measuring progress. Auxiliary enterprise sales and services contracts will generally constitute a single performance obligation as there is a single promise. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees with separate contracts for each type of service. Housing, dining services and parking fees are invoiced to undergraduate students at the beginning of each academic period. Payment is due upon invoice issuance. Graduate students and undergraduates who live off campus sign rental agreements providing for monthly rent payments. Generally, contracts for services in this category have a duration of one year or less. A contract liability is recorded for the delivery of performance obligations that is not completed prior to the fiscal year end.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

Educational Activities – Sales and Services

Clinical trial revenue is earned over-time as the university provides services. The transaction price is negotiated with the customer and is usually based on standard rates for clinical services and the expected cost to complete the contract. Payment terms under these contracts vary but generally provide for the right to invoice the customer as work progresses, either based on units performed or the achievement of billing milestones. The university has determined that an input method using costs incurred as a basis to estimate revenue earned best depicts the pattern of transfer of control to the customer. In those limited cases where prepayments are significant, revenue is deferred until earned and a contract liability is recorded. Such amounts are reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Contracts in other educational sales and services cover a broad range of activities including laboratory services, executive education program fees and royalties. Revenue from the contracts in this category is earned over time as services are rendered. The measure of progress varies according to the nature of the services provided. Invoicing to customers is performed in the cadence required under the contracts and amounts invoiced generally are considered due upon receipt. Accruals for services provided but not yet invoiced are recorded at year end. Fees for executive education programs are often received in advance of the program and represent a contract liability. Such amounts are reported as deferred revenue and contract liabilities in the consolidated statement of financial position.

Affiliated Hospital Revenues

Affiliated hospital revenue is earned over-time as the various services are provided as an integrated performance obligation as more fully described in footnote 13. The measure of progress towards completion of those obligations is based on the day-to-day operations of the university's School of Medicine and the affiliated hospitals. Payments are received under the agreement semiannually. Amounts receivable under the agreement are \$93,955 and \$88,097 at June 30, 2024 and 2023 respectively.

Operating Results

The university's measure of operations as presented in the consolidated statements of activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the consolidated statements of activities as incurred for employee compensation, depreciation, interest, and supplies, services and other. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, contributions to be held in perpetuity, and other non-operating amounts.

Income Taxes

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income, or consolidated for-profit affiliates incur taxes. The university is also subject to excise tax on net investment income and executive compensation. A provision for such taxes is included within accounts payable and accrued expenses on the consolidated statement of financial position and in investment returns net of endowment spending on the consolidated statement of activities.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

Management believes the university has no uncertain tax positions that require disclosure or adjustment to the consolidated financial statements.

Related Parties

The university has a number of related party entities, many of which are included in the consolidated financial statements as disclosed in footnote 1. The university is also party to affiliation agreements with hospitals for which significant related party transactions are described in footnote 6 and 13.

Members of the university's Board of Trustees, officers, and employees may periodically be directly or indirectly associated with organizations doing business with the university. Accordingly, the university has written conflict of interest policies that require disclosure of conflicts which may include financial interests in, or employment or board service with affiliated entities. Such relationships are subject to review and approval and may result in measures taken to manage any actual or perceived conflicts. Transactions between the university and members of its Board of Trustees, officers, employees, and their related entities, while not considered material to the consolidated financial statements, can include loans reported in accounts and notes receivables as well as contributions reported in gift revenue and pledges receivable.

The university invests in equity securities that are limited partnerships or equivalent entities which could be considered related parties.

Recent Accounting Pronouncements

ASU 2016-13, *Measurement of Credit Losses on Financial Instruments*, was issued by the FASB during June 2016 and was early adopted by the university during fiscal year 2021 with no significant impact to the university's consolidated financial statements. Subsequent updates, primarily codification improvements, have been made to Credit Losses (collectively, ASC 326) in recent years to expand upon or clarify proper accounting for the measurement of credit losses on financial instruments. The university has evaluated all subsequent updates and determined that no additional changes are needed to the consolidated financial statements or footnote disclosures.

During December 2023, the FASB issued ASU 2023-08, *Accounting for and Disclosure of Crypto Assets* which requires in-scope crypto assets to be measured at fair value with subsequent gains and losses recognized as change in net assets. This standard is effective for fiscal years beginning after December 15, 2024. Although not expected to be significant, university management is evaluating the impact this will have on the financial statements beginning in fiscal year 2026.

2. Fair Value

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university's assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2024, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$916,329.

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2024
Investments					
Public equity					
Domestic	\$ 38,875	\$ -	\$ -	\$ 1,055,572	\$ 1,094,447
International	235,729	-	-	1,713,925	1,949,654
Fixed income - Nominal	-	1,304,884	-	-	1,304,884
Absolute return	-	-	499	704,218	704,717
Private capital	-	-	250,416	7,456,226	7,706,642
Short-term investments	261,619	11,110	-	-	272,729
Real assets	57,223	-	78,746	1,031,790	1,167,759
Other investments	366,200	17,412	63,107	103	446,822
Total investments at fair value	959,646	1,333,406	392,768	11,961,834	\$ 14,647,654
Investments not reported at fair value					
Affiliates - Equity basis	-	-	-	-	41,971
Accrued investment income	-	-	-	-	8,314
Total investments	\$ 959,646	\$ 1,333,406	\$ 392,768	\$ 11,961,834	\$ 14,697,939

The following table presents the financial instruments carried at fair value as of June 30, 2023, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$880,691.

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2023
Investments					
Public equity					
Domestic	\$ 163,517	\$ -	\$ 20,675	\$ 499,195	\$ 683,387
International	156,593	-	-	2,033,971	2,190,564
Fixed income - Nominal	-	1,298,983	-	-	1,298,983
Absolute return	-	-	476	672,715	673,191
Private capital	-	-	244,918	7,142,353	7,387,271
Short-term investments	378,660	5,226	-	-	383,886
Real assets	28,054	-	72,155	838,494	938,703
Other investments	621,067	23,093	63,759	165	708,084
Total investments at fair value	1,347,891	1,327,302	401,983	11,186,893	\$ 14,264,069
Investments not reported at fair value					
Affiliates - Equity basis	-	-	-	-	40,723
Accrued investment income	-	-	-	-	6,779
Total investments	\$ 1,347,891	\$ 1,327,302	\$ 401,983	\$ 11,186,893	\$ 14,311,571

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all. Trustees determine the valuation for beneficial interest trusts and split-interest agreements.

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private capital investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2024:

Investments	Fair Value June 30, 2024	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 3,044,101	\$ -	No Limit	Daily to annually, with same day-180 day notice	Lock-up provision periods range from none to 4 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	1,577,613	-	No Limit	Daily, 1-2 days notice	No lock-up provision
Absolute return	704,717	-	No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion.
Private capital	7,706,642	1,489,572	0 - 25 Years	Not eligible for redemption	Not redeemable
Real assets	1,167,759	237,438	0 - 10 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 14,200,832</u>	<u>\$ 1,727,010</u>			

Footnote (1): Includes \$15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2023:

Investments	Fair Value June 30, 2023	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 2,873,951	\$ -	No Limit	Daily to annually, with same day-180 day notice	Lock-up provision periods range from none to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	1,682,869	-	No Limit	Daily, 1-2 days notice	No lock-up provision
Absolute return	673,191	-	No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion.
Private capital	7,387,271	1,696,758	0 - 26 Years	Not eligible for redemption	Not redeemable
Real assets	938,703	307,701	0 - 11 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 13,555,985</u>	<u>\$ 2,004,459</u>			

Footnote (1): Includes \$15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Public Equities

Public equities include investments in publicly-traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled commingled funds which are valued at NAV as described above. Investments held in custody accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to equity hedged and event driven. These funds are valued at net asset value as described above.

Private Capital

Investments in private capital strategies are made in targeted categories including growth equity, venture capital, distressed credit, and corporate finance. The majority of these assets are in non-redeemable drawdown fund structures and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in non-redeemable drawdown fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

Level Three Investments

The following tables roll forward the consolidated statement of financial position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2024 and 2023.

	Balance June 30, 2023	Net Realized and Unrealized Gains (Losses)	Purchases, Sales and Settlements Net	Transfers in/(out) of Level 3, net	Balance June 30, 2024
Investments (by strategy)					
Private capital	\$ 244,918	\$ 11,097	\$ (5,599)	\$ -	\$ 250,416
Real assets	72,155	3,361	3,230	-	78,746
Absolute return	476	23	-	-	499
Public equity	20,675	1,467	(22,142)	-	-
Other investments	63,759	2,526	(2,177)	(1,001)	63,107
Total	<u>\$ 401,983</u>	<u>\$ 18,474</u>	<u>\$ (26,688)</u>	<u>\$ (1,001)</u>	<u>\$ 392,768</u>

	Balance June 30, 2022	Net Realized and Unrealized Gains (Losses)	Purchases, Sales and Settlements Net	Transfers in/(out) of Level 3, net	Balance June 30, 2023
Investments (by strategy)					
Private capital	\$ 328,880	\$ (97,330)	\$ 8,368	\$ 5,000	\$ 244,918
Real assets	20,134	(438)	7,871	44,588	72,155
Absolute return	-	(44)	-	520	476
Public equity	21,759	(1,084)	-	-	20,675
Other investments	60,141	6,220	(1,363)	(1,239)	63,759
Total	<u>\$ 430,914</u>	<u>\$ (92,676)</u>	<u>\$ 14,876</u>	<u>\$ 48,869</u>	<u>\$ 401,983</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2024 and 2023 respectively, reported as investment returns net of endowment spending in the consolidated statements of activities by type of investment is:

	2024	2023
Private capital	\$ 4,975	\$ (46,968)
Real assets	3,004	(1,196)
Absolute Return	(205)	(44)
Public equity	-	(1,083)
Other investments	1,638	1,837
Total	<u>\$ 9,412</u>	<u>\$ (47,454)</u>

3. Investment Return

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private capital categories, report investment returns net of fees.

	2024	2023
Investment income	<u>\$ 95,018</u>	<u>\$ 72,234</u>
Pooled endowment dividends and interest income, net of investment management fees	(50,414)	(53,596)
Pooled endowment distribution in excess of income	626,359	623,385
Pooled endowment spending distribution	575,945	569,789
Investment gains (losses), net	1,073,305	(313,738)
Gains distributed as endowment distribution	(626,359)	(623,385)
Investment gains (losses) net of endowment spending distribution	446,946	(937,123)
Net investment return	<u>\$ 1,117,909</u>	<u>\$ (295,100)</u>

4. Endowment

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2024, the university's endowment consists of 4,410 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as net assets with donor restrictions, (a) the original value of gifts donated to the donor-restricted endowment, (b) the original value of subsequent gifts to the donor-restricted endowment, (c) accumulations to the donor-restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of donor-restricted endowment funds that are not restricted in perpetuity are considered restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2024:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$ -	\$ 6,991,404	\$ 6,991,404
Board-designated endowment funds	4,439,294	575,328	5,014,622
Total endowment funds	<u>\$ 4,439,294</u>	<u>\$ 7,566,732</u>	<u>\$ 12,006,026</u>

Changes in endowment net assets for the year ended June 30, 2024:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	<u>\$ 4,279,133</u>	<u>\$ 7,210,181</u>	<u>\$ 11,489,314</u>
Investment return			
Net investment income	(19,950)	(29,752)	(49,702)
Net increase in investments (realized and unrealized)	416,632	643,817	1,060,449
Total investment return	396,682	614,065	1,010,747
Gifts	66	86,437	86,503
Appropriation of endowment assets for expenditure	(227,918)	(348,027)	(575,945)
Net transfers of funds	28,773	26,370	55,143
Allocation of endowment return to treasurer's investment pool	(43,221)	(29,434)	(72,655)
Other activity	5,779	7,140	12,919
Endowment net assets, end of year	<u>\$ 4,439,294</u>	<u>\$ 7,566,732</u>	<u>\$ 12,006,026</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

Of the amount classified as endowment net assets with donor restrictions, \$4,520,483 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment net asset composition by type of fund as of June 30, 2023:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$ -	\$ 6,686,908	\$ 6,686,908
Board-designated endowment funds	<u>4,279,133</u>	<u>523,273</u>	<u>4,802,406</u>
Total endowment funds	<u>\$ 4,279,133</u>	<u>\$ 7,210,181</u>	<u>\$ 11,489,314</u>

Changes in endowment net assets for the year ended June 30, 2023:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	<u>\$ 4,531,534</u>	<u>\$ 7,711,224</u>	<u>\$ 12,242,758</u>
Investment return			
Net investment income	(21,949)	(30,919)	(52,868)
Net decrease in investments (realized and unrealized)	<u>(123,111)</u>	<u>(176,607)</u>	<u>(299,718)</u>
Total investment return	(145,060)	(207,526)	(352,586)
Gifts	73	92,228	92,301
Appropriation of endowment assets for expenditure	(233,346)	(336,443)	(569,789)
Net transfers of funds	34,426	(35,363)	(937)
Allocation of endowment return to treasurer's investment pool	87,624	(28,762)	58,862
Other activity	<u>3,882</u>	<u>14,823</u>	<u>18,705</u>
Endowment net assets, end of year	<u>\$ 4,279,133</u>	<u>\$ 7,210,181</u>	<u>\$ 11,489,314</u>

Of the amount classified as endowment net assets with donor restrictions, \$4,352,086 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

Endowment by Purpose

The purpose of endowment funds as of June 30, 2024:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 2,856,017	\$ 4,984,782	\$ 7,840,799
Restricted for student assistance	1,235,956	1,658,796	2,894,752
Restricted for buildings and renovations	347,321	889,223	1,236,544
Life income	-	33,931	33,931
Total endowment net assets	\$ 4,439,294	\$ 7,566,732	\$ 12,006,026

The purpose of endowment funds as of June 30, 2023:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 2,752,888	\$ 4,746,584	\$ 7,499,472
Restricted for student assistance	1,190,110	1,572,685	2,762,795
Restricted for buildings and renovations	336,135	855,565	1,191,700
Life income	-	35,347	35,347
Total endowment net assets	\$ 4,279,133	\$ 7,210,181	\$ 11,489,314

Endowment Funds with Deficits

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they remain classified as net assets with donor restrictions. Deficits of this nature were immaterial as of June 30, 2024 and 2023. The deficits resulted largely from unfavorable market fluctuations.

Return Objectives and Risk Parameters

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2024, the spending rate from the pooled endowment was 4.9% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

The university's endowment assets at June 30 are as follows:

	2024	2023
Pooled endowment and other funds	\$ 12,951,263	\$ 12,390,790
Life income trusts and pools	66,512	69,602
Externally administered trusts	35,478	33,474
Separately invested endowment	8,236	9,037
Total	13,061,489	12,502,903
Less: Operating funds invested in pool	(1,015,074)	(991,129)
Net endowment assets	<u>\$ 12,046,415</u>	<u>\$ 11,511,774</u>

The amounts above include term endowments of \$139,503 and \$132,188 as of June 30, 2024 and 2023, respectively.

5. Liquidity and Availability of Resources

At June 30, 2024 and 2023, the university's financial assets available for general expenditures within one year of the balance sheet date are as follows:

	2024	2023
Total assets at year end	\$ 20,486,807	\$ 19,792,327
Less:		
Accounts and notes receivable due in more than one year	(96,107)	(92,742)
Pledges receivable unavailable for general expenditure	(273,473)	(294,173)
Donor-restricted endowment funds	(7,248,777)	(6,831,617)
Board-designated endowment funds	(4,797,638)	(4,680,157)
Other long-term investments	(1,647,649)	(1,783,702)
Right-of-use assets	(88,882)	(93,447)
Other assets	(433,132)	(362,291)
Fixed assets	(3,794,317)	(3,566,162)
Total financial assets available within one year	<u>\$ 2,106,832</u>	<u>\$ 2,088,036</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

The university's endowment funds consist of donor-restricted and board-designated endowment funds. As described in Note 4, the university has an endowment spending distribution policy with a spending rate range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For fiscal year 2024, the Board of Trustees approved a spending rate which will generate an endowment payout equaling or exceeding that of fiscal year 2023, including an allocation to the treasurer's investment pool, which will be available for operations during fiscal year 2024.

In addition to these available financial assets, the university's annual expenditures will be primarily funded by current year operating revenues including tuition, patient services income, and sponsored research income. As part of the university's liquidity management, a policy is in place to structure its financial assets to be available as general expenditures, liabilities, and other obligations come due. The university also invests cash in excess of daily requirements in short-term investments. Furthermore, although the university does not intend to spend from its board-designated endowment funds other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment that are free from investment restrictions could be made available if necessary. Other long-term investments are primarily composed of amounts designated by the university as reserves. Such investments are without donor restriction and could be drawn upon in the event of extreme stress. In the event of an unanticipated liquidity need, the university could also draw upon \$430,000 of available lines of credit at June 30, 2024.

6. Accounts and Notes Receivable

Accounts and notes receivable at June 30 were as follows:

	2024	2023
Patient services	\$ 594,512	\$ 526,077
Student and parent loans	68,282	70,468
Due from affiliate hospitals	252,320	190,783
Sponsored project receivables	167,208	158,210
Other	<u>153,674</u>	<u>159,244</u>
	1,235,996	1,104,782
Less: Allowance for contractual adjustments and doubtful accounts	<u>(399,066)</u>	<u>(381,567)</u>
Total	<u>\$ 836,930</u>	<u>\$ 723,215</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

7. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2024 and 2023 consists of the following:

	Rates at June 30, 2024	Maturity	2024	2023
Missouri Health and Educational Facilities Authority				
\$88,000 of 2000B and C Series				
Variable Rate Bonds, due in full	3.60% - 4.90%	March 1, 2040	\$ 88,000	\$ 88,000
\$25,135 of 2003B Series				
Variable Rate Bonds, due in full	4.00% - 4.90%	February 15, 2033	25,135	25,135
\$77,495 of 2011C Series Revenue Bonds, due serially from November 15, 2012 to November 15, 2037				
	0.75% - 5.06%	November 15, 2037	42,165	44,740
\$200,785 of 2012A Series Revenue Bonds, due serially from February 15, 2023 to February 15, 2047				
	2.39% - 3.69%	February 15, 2047	180,785	180,785
\$150,000 of 2014A Series Revenue Bonds, due in full				
	4.07%	October 15, 2044	150,000	150,000
\$402,920 of 2016A Series Revenue Bonds, due in full January 15, 2036 (\$109,300) and January 15, 2046 (\$293,620)				
	3.47% - 3.65%	January 15, 2036 and 2046	402,920	402,920
\$272,750 of 2016 B Series Revenue Bonds, due in full				
	3.09%	September 15, 2051	272,750	272,750
\$375,000 of 2017 A Series Revenue Bonds, due in full				
	3.65%	August 15, 2057	375,000	375,000
\$450,000 of 2020 A Series Revenue Bonds, due in full				
	3.23%	May 15, 2050	450,000	450,000
Other Bonds:				
\$131,435 of 2015A Series Taxable Bonds, due in full				
	3.79%	October 15, 2055	131,435	131,435
\$1,000,000 of 2022 Series Taxable Bonds, due in full on April 15, 2054 (\$500,000) and April 15, 2122 (\$500,000)				
	3.52% - 4.35%	April 15, 2054 and 2122	1,000,000	1,000,000
Other notes payable with various maturities			162,407	153,484
Total outstanding notes and bonds payable			3,280,597	3,274,249
Unamortized original issue premiums/discounts and cost of issuance, net			(14,289)	(14,774)
Total			<u>\$3,266,308</u>	<u>\$3,259,475</u>

Bonds payable are redeemable at the option of the university at various times from 2024 through 2122. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintains a ratio of expendable financial resources to bonds and notes payable of at least 1.25 times. The university is in compliance with this covenant. During 2024 and 2023, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled \$116,299 and \$116,923, respectively.

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

Maturities on notes and bonds payable for the next five fiscal years are as follows:

2025	25,892
2026	134,837
2027	32,522
2028	2,607
2029	2,722
Thereafter	3,082,017

The university has other lines of credit, which generally expire annually, aggregating to \$430,000, of which \$430,000 is available at June 30, 2024. The university expects that these lines of credit will be renewed but can make no assurances.

8. Operating Leases

The university and its consolidated affiliates primarily lease laboratories, office space, and medical offices for educational, research, and patient care purposes under operating leases expiring through fiscal 2034. At June 30, 2024 and 2023, the weighted average remaining lease term was 4.9 and 5.8 years and the weighted average discount rate was 4.01% and 3.65%, respectively. Lease expense is included in supplies, services, and other on the consolidated statement of activities.

The undiscounted cash flows due by fiscal year related to significant non-cancelable operating leases with initial terms in excess of one year as of June 30, 2024, along with a reconciliation to the discounted amount recorded as of June 30, 2024 were as follows:

2025	27,089
2026	26,247
2027	20,714
2028	15,953
2029	9,537
Thereafter	13,382
Total minimum lease payments	<u>\$ 112,922</u>
Less: Imputed interest	<u>(14,207)</u>
Total lease liabilities	<u>\$ 98,715</u>

9. Derivative and Other Financial Instruments

The university utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the university uses a third-party manager to execute, settle and manage the positions on a non-discretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and quarterly as well as at June 30, with the resulting changes in the values of the contracts either

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

added to or deducted from the university's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the consolidated statements of activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the university invests pose no off-balance sheet risk to the university due to the limited liability structure of the investments. Derivatives are also used to manage operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

10. Functional Expenses

Operating expenses are reported on the consolidated statements of activities in natural categories. Expenses reported by functional categories include allocations of costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs.

Operating expenses by functional and natural classification for the year ended June 30, 2024 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,831,889	\$ 1,090,341	\$ 81,708	\$ 22,267	\$ 3,026,205
Research	484,891	288,640	79,214	39,933	892,678
Academic Support	399,032	50,998	25,817	13,970	489,817
Student Services	69,864	79,765	8,091	3,584	161,304
Institutional Support	244,746	38,943	12,238	489	296,416
Auxiliary Enterprises	23,014	70,153	47,885	24,051	165,103
Other	25,679	24,896	568	493	51,636
Total	\$ 3,079,115	\$ 1,643,736	\$ 255,521	\$ 104,787	\$ 5,083,159

Operating expenses by functional and natural classification for the year ended June 30, 2023 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,668,440	\$ 972,454	\$ 69,197	\$ 33,256	\$ 2,743,347
Research	435,867	279,356	67,630	17,873	800,726
Academic Support	367,454	54,389	23,522	12,275	457,640
Student Services	65,834	66,591	6,179	2,910	141,514
Institutional Support	186,142	38,710	16,630	2,078	243,560
Auxiliary Enterprises	20,971	58,700	41,612	25,154	146,437
Other	25,603	11,309	199	192	37,303
Total	\$ 2,770,311	\$ 1,481,509	\$ 224,969	\$ 93,738	\$ 4,570,527

Washington University

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(All amounts in thousands of dollars)

11. Commitments and Contingencies

At June 30, 2024 and 2023, the university had outstanding commitments under certain construction contracts in the amount of \$122,207 and \$248,572, respectively.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the consolidated statements of financial position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2024 and 2023, respectively, were \$113,686 and \$104,012. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, consolidated statements of activities, financial position or liquidity of the university.

12. Retirement Plan

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. The amount of contribution made by the university is based on employee's hire date and/or age. While participant contributions are fully vested when contributions are made, university contributions are subject to vesting provisions based on employee's hire date. The university's share of the cost of these benefits in 2024 and 2023 was \$153,327 and \$121,010, respectively.

13. Agreements with Affiliated Hospitals

The university has an affiliation agreement with BJC in relation to Barnes Jewish Hospital (BJH), St. Louis Children's Hospital (SLCH), and Barnes Jewish West County Hospital (BJWCH), collectively the Hospitals, which expires December 31, 2027, but may be canceled upon a one-year written notice by either party. This agreement relates to various operating

Washington University
Notes to Consolidated Financial Statements
June 30, 2024 and 2023

(All amounts in thousands of dollars)

activities of the Hospitals including Orthopedic Center (OC) in Chesterfield, Siteman Cancer Center – South County, Center for Advanced Medicine (CAM) in South County, BJH Psychiatric Support Center (PSC), Children’s Specialty Care Center in Town and Country, and Children’s Specialty Care Center in South County.

Under the terms of the affiliation agreement, the university trains and supervises medical residents and interns and manages certain clinical and research activities of the Hospitals. The Hospitals compensate the university for services provided through a fixed annual base payment (adjusted annually for inflation) plus an additional variable payment based on the combined net operating income of the Hospitals. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. Payments to the university under affiliation agreements are reported as affiliated hospital revenue on the consolidated statements of activities (see footnote 1). During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of \$35,590 and \$40,855 were received or accrued as gifts on the consolidated statements of activities under the agreement during 2024 and 2023, respectively.

14. Subsequent Events

The university has performed an evaluation of subsequent events through September 27, 2024, which is the date the consolidated financial statements were issued. In July 2024, the university signed a revised and extended 45-year affiliation agreement with BJC Health System; expanding the communities served and enhancing the services provided under the existing agreement (see footnote 13). As part of the agreement, effective July 1, 2024, the university transitioned its oncology chemotherapy infusion services and retail pharmacy services to hospital outpatient services of the BJC Health System. Within the consolidated statement of activities as of June 30, 2024, for the service lines that have been subsequently transferred, the university recognized patient services revenue of approximately \$625,000 and operating expenses of approximately \$550,000. The university will continue to receive compensation for services provided and clinical operating performance, including the transitioned service lines, based on revised calculations which will be reflected in the financial statements for the period ending June 30, 2025.

Supplemental Information

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Research and Development Cluster					
DEPARTMENT OF DEFENSE					
Advanced Research Projects Agency					
Research and Technology Development	12.910			\$ 1,543,477	\$ 205,964
Research and Technology Development	12.910	Columbia University	HR0011-22-2-0022	116,489	-
Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	73,224	-
Defense Advanced Research Projects Agency					
Defense Advanced Research Projects Agency	12.RD	Charles River Analytics Inc	N6600121C4013	673,310	-
Defense Advanced Research Projects Agency	12.RD	Tai-Yang Research Company	N66001-24-C-4016	56,449	-
Defense Intelligence Agency					
Centers for Academic Excellence	12.598	Georgia Institute Of Technology	W911W6-21-2-001	83,066	-
Defense Threat Reduction Agency					
Defense Threat Reduction Agency	12.RD	Massachusetts General Hospital	HDTRA122C0006	283,407	-
Defense Threat Reduction Agency	12.RD	Najit Technologies, Inc.	W15QKN1691002	204,061	-
Defense Threat Reduction Agency	12.RD	University Of Pittsburgh	W15QKN1691002	1,347,213	-
Department of Defense					
Department of Defense	12.RD	Barron Associates	W81XWH22C0068	63,311	-
Department of Defense	12.RD	BlueHalo	HM0476-21-C-0004	95,803	-
Department of Defense	12.RD	BlueHalo	HQ0860-21-C-7137	89,613	-
Department of Defense	12.RD	Cornerstone Research Group Inc	W81XWH-22-11062	118,439	-
Department of Defense	12.RD	Cure HHT Foundation	W81XWH2110827	430	-
Department of Defense	12.RD	Eccalon LLC	47QTCa18DooDK	18,054	-
Department of Defense	12.RD	HII Mission Technologies Corp.	FA807518D0002	5,681	-
Department of Defense	12.RD	Johns Hopkins University	X81XWH1620060	(825)	-
Department of Defense	12.RD	Mainstream Engineering Corporation	HQ086023C7520	599	-
Department of Defense	12.RD	NervGen Pharma Corp	W81XWH1590001	348,897	-
Department of Defense	12.RD	University Of Alabama Birmingham	W81XWH2230001	5,720	-
Department of Defense	12.RD	University Of Pittsburgh	W81XWH209C003	383,456	-
Department of the Air Force, Material Command					
Air Force Defense Research Sciences Program	12.800			588,169	-
Air Force Defense Research Sciences Program	12.800	Pennsylvania State University	FA95502110202	82,506	-
Air Force Defense Research Sciences Program	12.800	Princeton University	FA95502010241	211,885	-
Air Force Defense Research Sciences Program	12.800	University of Colorado	FA9550-20-1-0076	71,271	-
Air Force Defense Research Sciences Program	12.800	University of Washington	FA9550-20-1-0074	96,989	-
Air Force Defense Research Sciences Program	12.800	West Virginia University	FA9550-21-1-0088	169,007	-
Air Force Defense Research Sciences Program	12.800	Worcester Polytechnic Institute	FA95502210054	57,075	-
Department of the Navy, Office of the Chief of Naval Research					
Basic and Applied Scientific Research	12.300			1,691,827	531,617
Basic and Applied Scientific Research	12.300	Indiana University–Purdue University Indianapolis	N000142112630	251,365	-
Basic and Applied Scientific Research	12.300	University Of California Davis	N000141712961	202,595	-
Basic and Applied Scientific Research	12.300	University Of Southern California	N000141812632	19,256	-
National Security Agency					
National Security Agency	12.RD	North Carolina State University	H98230-1 9-D-00 12/0004	28,767	-
National Security Agency	12.RD	North Carolina State University	H98230-1 9-D-00 12/0004LAS	128,806	-
Basic, Applied, and Advanced Research in Science and Engineering	12.630	Battelle Memorial Institute	W911SR-15-2-0001	18,144	-
Basic, Applied, and Advanced Research in Science and Engineering	12.630	University Of Iowa	FA95502010346	91,477	-
Basic, Applied, and Advanced Research in Science and Engineering	12.630	University of Pennsylvania	W911NF-17-2-0181	8,813	-
U.S. Army Material Command					
Basic Scientific Research	12.431			702,040	227,016
Basic Scientific Research	12.431	Missouri University of Science and Technology	W911NF2120262	131,639	-
Basic Scientific Research	12.431	University Of Kentucky	FA95502110227	18,644	-
Basic Scientific Research	12.431	University of Michigan	W911NF1810208	136,238	-
Basic Scientific Research	12.431	University of Minnesota	W911NF1810240	104,598	-
Basic Scientific Research	12.431	University of Southern California	W911NF2110327	28,407	-
U.S. Army Medical Command					
Military Medical Research and Development	12.RD			814,298	365,008
Military Medical Research and Development	12.420			12,508,540	1,564,147
Military Medical Research and Development	12.420	Cedars Sinai Medical Center	HT94252310269	110,768	-
Military Medical Research and Development	12.420	Fred Hutchinson Cancer Center	W81XWH-22-2-0003	329,030	-
Military Medical Research and Development	12.420	IDBiologics Inc	W81XWH1910405	385	-
Military Medical Research and Development	12.420	Johns Hopkins University	W81XWH10580	43,456	-
Military Medical Research and Development	12.420	Saint Louis University	W81XWH2010241	(407)	-
Military Medical Research and Development	12.420	University Of Alabama Birmingham	W81XWH1720037	2,975	-
Military Medical Research and Development	12.420	University Of Alabama Birmingham	W81XWH2210924	390,895	-
Military Medical Research and Development	12.420	University of Illinois at Urbana-Champaign	W81XWH2110062	9,906	-
Military Medical Research and Development	12.420	University Of Iowa	W81XWH2210683	123,945	-
Military Medical Research and Development	12.420	University of Missouri System	W81XWH2110173	16,429	-
Military Medical Research and Development	12.420	University Of North Carolina Chapel Hill	W81XWH1910117	(3,066)	-
Military Medical Research and Development	12.420	University of Pittsburgh	W81XWH1720073	2,185	-
Military Medical Research and Development	12.420	University Of South Carolina	W81XWH1920051	32,770	-
Military Medical Research and Development	12.420	University Of Texas MD Anderson Cancer Center	HT94252310239	81,665	-
Military Medical Research and Development	12.420	Veterans Research & Education Foundation of St. Louis	W81XWH2010785	7,715	-
Military Medical Research and Development	12.420	Veterans Research & Education Foundation of St. Louis	W81XWH2210602	65,051	-
Military Medical Research and Development	12.420	Weill Medical College of Cornell University	W81XWH1810667	(15,624)	-
TOTAL DEPARTMENT OF DEFENSE				<u>24,870,218</u>	<u>2,893,752</u>

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
DEPARTMENT OF EDUCATION					
Office of Postsecondary Education					
Overseas Programs - Doctoral Dissertation Research Abroad	84.022			36,691	-
Office of Special Education and Rehabilitative Services					
Education Research, Development and Dissemination	84.305	Indiana University	R305N210035	32,412	-
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325			667,620	-
TOTAL DEPARTMENT OF EDUCATION				736,723	-
DEPARTMENT OF ENERGY					
Department of Energy					
Office of Science Financial Assistance Program	81.049			5,549,284	667,791
Office of Science Financial Assistance Program	81.049	Aerosol Dynamics Inc	DESC0023627	117,700	-
Office of Science Financial Assistance Program	81.049	Dartmouth College	DE-SC0022267	50,633	-
Office of Science Financial Assistance Program	81.049	Georgia Institute Of Technology	DE-SC0012577	(598)	-
Office of Science Financial Assistance Program	81.049	Iowa State University Of Science And Technology	DE-SC0023495	109,663	-
Office of Science Financial Assistance Program	81.049	Michigan State University	DE-SC0013617	154,473	-
Office of Science Financial Assistance Program	81.049	TDA Research Inc	DESC0018502	52,753	-
Office of Science Financial Assistance Program	81.049	University Of Delaware	DE-SC0023085/UDR0000327	112,917	-
Office of Science Financial Assistance Program	81.049	University of Texas at Dallas	DE-SC0022069	63,276	-
Office of Science Financial Assistance Program	81.049	University Of Wisconsin	DE-SC0021985	92,063	-
Renewable Energy Research and Development	81.087			1,356,350	344,706
Renewable Energy Research and Development	81.087	University at Buffalo	DE-EE0010750	17,211	-
Fossil Energy Research and Development	81.089			1,514,548	444,433
Fossil Energy Research and Development	81.089	GTI Energy	DE-FE0031909	118,052	-
Fossil Energy Research and Development	81.089	Texas A&M University	DE-EE0032108	110,725	-
Stewardship Science Grant Program	81.112			101,825	-
Stewardship Science Grant Program	81.112	Krell Institute	DENA0003960	41,333	-
Stewardship Science Grant Program	81.112	Texas A&M University	DENA0003841	45,312	-
Stewardship Science Grant Program	81.112	Texas A&M University	DE-NA0004150	18,310	-
Advanced Research Projects Agency - Energy	81.135			766,776	441,226
Department of Energy	81.RD	Fermi National Accelerator Lab	DEAC0207CH11359	300,925	-
Department of Energy	81.RD	Honeywell International Inc.	N000522331	18,363	-
Department of Energy	81.RD	Honeywell International Inc.	N000523128	43,607	-
Department of Energy	81.RD	Lawrence Berkeley National Laboratory	DEAC0205CH11231	(4,540)	-
Department of Energy	81.RD	National Renewable Energy Laboratory	DE-AC36-08GO28308	100,601	-
Department of Energy	81.RD	Pacific Northwest National Laboratory	DE-AC05-76RL01830	351,987	-
TOTAL DEPARTMENT OF ENERGY				11,203,639	1,898,156
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Children and Families					
Child Abuse and Neglect Discretionary Activities	93.670			50,598	33,741
Child Abuse and Neglect Discretionary Activities	93.670	Vision for Children at Risk Inc	PACTSTL	111,356	-
Administration for Community Living					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433			198,201	7,269
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	University of Wisconsin, Milwaukee	90IFDV0006	(941)	-
ACL Assistive Technology State Grants for Protection and Advocacy	93.843	Tulane University	5R01HL12242608	71,048	-
Advanced Research Projects Agency for Health (ARPA-H)					
Advanced Research Projects Agency for Health (ARPA-H)	93.384			1,342,150	22,225
Agency for Healthcare Research and Quality					
Research on Healthcare Costs, Quality and Outcomes	93.226			2,648,243	494,397
COVID-Research on Healthcare Costs, Quality and Outcomes	93.226			462,728	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Children's Hospital Of Philadelphia (The)	5R01HS02742803	56,914	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Denver Health and Hospital Authority	1R01HS029153-01	29,046	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Denver Health and Hospital Authority	5R01HS02915302	47,727	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Ohio University	1R03HS02940701A1	8,975	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Thomas Jefferson University	1R18HS029791-01	29,474	-
COVID-Research on Healthcare Costs, Quality and Outcomes	93.226	Trustees Of Columbia University In the City Of New York	1R01HS02845401A1	205,151	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Tufts College	1R01HS028650-01A1	12,810	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University Of Chicago	5R01HS02780402	52,366	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Michigan	1R18HS028787-01A1	23,095	-
Centers for Disease Control					
Chronic Diseases: Research, Control, and Prevention	93.068	Armor Medical Inc	1R43DP006818-01-00	37,122	-
Birth Defects and Developmental Disabilities, Prevention, and Surveillance	93.073			286,692	52,815
Birth Defects and Developmental Disabilities, Prevention, and Surveillance	93.073	Johns Hopkins University	5U01DD00129702	23,352	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080			56,330	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center at Houston	NU27DD000020-01-00	15,105	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084			1,747,786	209,550
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Emory University	6U54CK000601-02-01	53,828	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	North Carolina State University	5U01CK00058703	41,353	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	North Carolina State University	5U01CK00058703	2,458	-
COVID-Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University Medical Center Obligated Group	U54CK000607	14,463	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Trustees Of The University Of Pennsylvania	6U54CK000610-03-01	18,008	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University Of Iowa	6 U54CK000613-01-01	10,578	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University Of Iowa	6U54CK00061301	196,568	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135			1,017,982	-
Injury Prevention and Control Research and State and Community Based programs	93.136			314,295	117,328
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	93.185			2,276,119	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
COVID-Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	93.185			47,298	
State Rural Hospital Flexibility Program	93.241	The National Association Of Chronic Disease Directors	5NU380T000286-05-02	188,965	-
Occupational Safety and Health Program	93.262			16,378	-
Occupational Safety and Health Program	93.262	Center for Construction Research and Training	U60OH009762	280,095	-
Occupational Safety and Health Program	93.262	Center for Construction Research and Training	U60-OH009762-11	46,647	-
Occupational Safety and Health Program	93.262	The Regents of the University of California	5R01OH01156104	140,033	-
Occupational Safety and Health Program	93.262	University Of Iowa	5U19OH00886817	39,785	-
Occupational Safety and Health Program	93.262	University Of Iowa	5U19OH00886818	81,167	-
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	University of Washington	NU50CK000515	12,567	-
Childhood Obesity Research Demonstration	93.349			259,895	171,245
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	Children's Hospital Corporation	6NU380T00028805	156,588	
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	The National Association Of Chronic Disease Directors	5NU380T0002863	(14,239)	1,204
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	The National Association Of Chronic Disease Directors	5NU380T0002864	334	
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	The National Association Of Chronic Disease Directors	5NU380T0002865	(9,781)	385
National Organizations for Chronic Disease Prevention and Health Promotion	93.800	National Association For Chronic Disease Director	5NU58DP00651003	30,378	5,626
National Organizations for Chronic Disease Prevention and Health Promotion	93.800	National Association For Chronic Disease Director	5NU58DP00651004	21,804	
National Organizations for Chronic Disease Prevention and Health Promotion	93.800	National Association For Chronic Disease Director	5NU58DP00651005	51,217	16,687
Capacity Building Assistance for High-Impact HIV Prevention	93.834			1,009,964	129,606
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978			968,647	37,158
Centers for Disease Control	93.RD			2,069,432	309,142
Centers for Disease Control	93.RD	St. Louis County	HE2022-0108	137,122	
Centers for Disease Control	93.RD	St. Louis County	HE2023-0012	93,945	51,009
Centers for Disease Control	93.RD	Vanderbilt University Medical Center	75D30122C14944	94,681	
Centers for Disease Control	93.RD	Wayne State University	75D30121C11813	111,819	-
Food and Drug Administration					
Food and Drug Administration_Research	93.103	Cumberland Pharmaceuticals	1R01FD00637101A1	19,156	-
Food and Drug Administration_Research	93.103	New York Medical College	5R01FD00636304	16,549	-
Food and Drug Administration_Research	93.103	Trustees Of Columbia University In the City Of New York	5R01FD00574504	23,836	-
Health Resources and Services Administration					
Maternal and Child Health Federal Consolidated Programs	93.110	Boston University	6 U1TMC31757-05-01	54,214	-
Maternal and Child Health Federal Consolidated Programs	93.110	Cure HHT Foundation	1UP4MC464040100	112,114	-
Maternal and Child Health Federal Consolidated Programs	93.110	University of Missouri System	AOC19380201/U4J47106	17,573	-
Maternal and Child Health Federal Consolidated Programs	93.110	University of Texas Health Science Center at Houston	5H30MC24051-12-00	21,848	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.453			1,052,029	89,081
Rural Health Research Centers	93.455	University of Iowa	2U1CRH20419-12-00	112,704	-
Rural Health Research Centers	93.455	University of Iowa	5U1GRH07633-14-00	(606)	-
Mental and Behavioral Health Education and Training Grants	93.732			820,841	-
IMMED Office of the Secretary of Health and Human Services					
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.863			465,418	-
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.RD	Technical Resources International Inc	HHS0100201400002I	17,293	-
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.RD	University of Pittsburgh	75A50123C00047	21,719	-
National Institutes of Health					
Environmental Health	93.113			1,280,160	119,208
Environmental Health	93.113	Dignity Health dba St. Joseph's Hospital & Medical Center	7R01ES026891-06	8,602	-
Environmental Health	93.113	Dignity Health dba St. Joseph's Hospital & Medical Center	7R01ES02148808	378,275	-
Environmental Health	93.113	New York University	1R01ES03546801	50,278	-
Environmental Health	93.113	Northwestern University	5R01ES03180903	10,105	-
Environmental Health	93.113	Trustees Of Columbia University In the City Of New York	5R01ES03061605	93,229	-
Environmental Health	93.113	University Of Louisville	5R01ES02984603	25,319	-
Environmental Health	93.113	University Of Maryland	5R01ES03430302	100,670	-
Environmental Health	93.113	University Of Southern California	5R01ES03396102	130,329	-
Oral Diseases and Disorders Research	93.121			1,444,370	38,900
Oral Diseases and Disorders Research	93.121	Case Western Reserve University	2R01DE026923-06A1	10,214	-
Oral Diseases and Disorders Research	93.121	Research Institute at Nationwide Children's Hospital	7R01DE02829604	18,201	-
Oral Diseases and Disorders Research	93.121	TetraImaging, LLC	1R1DE02972701A1	3,200	-
Oral Diseases and Disorders Research	93.121	Stanford University	1R01DE030894-01A1	23,740	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh	1R01DE033322-01	333,891	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	P42ES023716	165,627	-
Human Genome Research	93.172			7,243,614	2,166,885
Human Genome Research	93.172	California Institute Of Technology	U24HG00222323	29,414	-
Human Genome Research	93.172	The Broad Institute Inc	5U24HG01026206	96,787	-
Human Genome Research	93.172	University of Pennsylvania	5R21HG01107902	60,808	-
Human Genome Research	93.172	University of California, Santa Cruz	5U01HG01097104	781,680	-
Human Genome Research	93.172	University Of North Carolina Chapel Hill	5U24HG00965006	69,987	-
Research Related to Deafness and Communication Disorders	93.173			5,397,922	642,467
Research Related to Deafness and Communication Disorders	93.173	Boystown National Research Hospital	5R01DC01833905	21,731	-
Research Related to Deafness and Communication Disorders	93.173	East Carolina University	5R01DC01770202	1,608	-
Research Related to Deafness and Communication Disorders	93.173	Northeastern University	7R01DC01950702	258,001	-
Research Related to Deafness and Communication Disorders	93.173	Ohio State University	5U01DC01892002	135,655	-
Research Related to Deafness and Communication Disorders	93.173	University Of Alabama Birmingham	5R01DC01598005	(245)	-
Research Related to Deafness and Communication Disorders	93.173	University Of Iowa	5R01DC01848803	213,106	-
Research Related to Deafness and Communication Disorders	93.173	University Of Pittsburgh	2R0DC01304806A1	60,646	-
Research Related to Deafness and Communication Disorders	93.173	University Of Pittsburgh	5R01HD07951208	112,626	-
Research Related to Deafness and Communication Disorders	93.173	University of Texas at Dallas	5R01DC01966002	15,767	-
Research Related to Deafness and Communication Disorders	93.173	University of Utah	5R01DC01131111	104,689	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity	Total	Passed to Sub-
	Listing Number		Identification Number	Expenditures	Recipients
Research Related to Deafness and Communication Disorders	93.173	Vanderbilt University	2RM1HG009034	50,484	-
Research and Training in Complementary and Integrative Health	93.213			2,044,870	24,817
Research and Training in Complementary and Integrative Health	93.213	University of Minnesota	5U54AT012307-02	9,384	-
Research and Training in Complementary and Integrative Health	93.213	Yale University	5R01AT01141902	203,699	-
National Center on Sleep Disorders Research	93.233			836,052	-
National Center on Sleep Disorders Research	93.233	Johns Hopkins University	3U01HL15056801S1	12,530	-
Mental Health Research Grants	93.242			43,934,916	7,434,161
Mental Health Research Grants	93.242	Allen Institute	1UM1MH13098001	157	-
Mental Health Research Grants	93.242	Allen Institute	5UM1MH13098002	507,332	-
Mental Health Research Grants	93.242	Chapman University	5P50MH09688908	22,956	-
Mental Health Research Grants	93.242	Children's Hospital Los Angeles	7R01MH12146203	109,359	-
Mental Health Research Grants	93.242	Columbia University	P50MH115843	20,942	-
Mental Health Research Grants	93.242	Duke University	1R01MH12983201	60,534	-
Mental Health Research Grants	93.242	Emory University	1R56MH12901901A1	32,706	-
Mental Health Research Grants	93.242	Emory University	5R01MH11469205	(39)	-
Mental Health Research Grants	93.242	EsperImage LLC	5R41MH13144902	221,823	-
Mental Health Research Grants	93.242	Harvard University	5R01MH12949303	274,198	-
Mental Health Research Grants	93.242	Icahn School Of Medicine At Mount Sinai	5R01MH13035402	19,716	-
Mental Health Research Grants	93.242	Mayo Clinic	5R01MH122258	55,870	-
Mental Health Research Grants	93.242	NeuroLux	5R44MH114944	11,050	-
Mental Health Research Grants	93.242	New York University	5P50MH11366203	12,474	-
Mental Health Research Grants	93.242	Northwestern University	3R01M12187704S1	58,192	-
Mental Health Research Grants	93.242	Northwestern University	5R01M12187704	771,746	-
Mental Health Research Grants	93.242	Nous Imaging Inc	4R44MH12127602	247,419	-
Mental Health Research Grants	93.242	Nous Imaging Inc	5R44MH12206603	200,140	-
Mental Health Research Grants	93.242	Nous Imaging Inc	5R44MH12456704	171,879	-
Mental Health Research Grants	93.242	Pennsylvania State University	1R01MH13000701	390,017	-
Mental Health Research Grants	93.242	Pennsylvania State University	R56MH126349	(1,114)	-
Mental Health Research Grants	93.242	Purdue University	5R01MH12621302	181,864	-
Mental Health Research Grants	93.242	Regents Of The University Of Minnesota	5R01MH09677310	435,939	-
Mental Health Research Grants	93.242	Regents Of The University Of Minnesota	5R01MH11696104	2,596	-
Mental Health Research Grants	93.242	Research Foundation for The State University of New York	5R34MS12408202	12,380	-
Mental Health Research Grants	93.242	Rosalind Franklin University of Medicine and Science	5R01MH13037502	83,742	-
Mental Health Research Grants	93.242	RTI International	1R01MH13156501A1	32,983	-
Mental Health Research Grants	93.242	Rutgers The State University Of NJ	5U524MH06845720	12,388	-
Mental Health Research Grants	93.242	The Miriam Hospital	5R01MH11465705	(416)	-
Mental Health Research Grants	93.242	The Regents of the University of California	5R01MH18221704	431,789	-
Mental Health Research Grants	93.242	The Regents of the University of California	5R24MH129166	263,963	-
Mental Health Research Grants	93.242	The Salk Institute for Biological Studies	UM1MH130994	757,334	-
Mental Health Research Grants	93.242	Trustees Of Columbia University In the City Of New York	5K01MH12231903	41	-
Mental Health Research Grants	93.242	Trustees Of Columbia University In the City Of New York	5R01MH12059704	10,245	-
Mental Health Research Grants	93.242	Universidad de O'Higgins	5U01MH11550204	(1,637)	-
Mental Health Research Grants	93.242	Universidad de O'Higgins	5U01MH11550205	(7,990)	-
Mental Health Research Grants	93.242	University Of Alabama Birmingham	4R33MH127155-03	17,054	-
Mental Health Research Grants	93.242	University Of California Los Angeles	5R01MH10002716	188,501	-
Mental Health Research Grants	93.242	University of Illinois Chicago	4R33MH119237-02	41,735	-
Mental Health Research Grants	93.242	University Of Maryland	1RF1MH12316301A1	24,244	-
Mental Health Research Grants	93.242	University of Missouri, St. Louis	5R01MH10855904	(12,356)	-
Mental Health Research Grants	93.242	University Of North Carolina Chapel Hill	1R01MH130441-01A1	15,486	-
Mental Health Research Grants	93.242	University Of North Carolina Chapel Hill	5K01MH114721-05	33,202	-
Mental Health Research Grants	93.242	University of Pennsylvania	1R01MH13296201A1	139,194	-
Mental Health Research Grants	93.242	University Of Rochester	5P50MH106435	440,359	-
Mental Health Research Grants	93.242	University of Washington	7P50MH126219-03	10,210	-
Mental Health Research Grants	93.242	Yale University	2P30MH062294-21	38,275	-
Mental Health Research Grants	93.242	Yale University	5P30MH06229419S1	21,233	-
Mental Health Research Grants	93.242	Yale University	5U01MH12463903	723,772	-
Alcohol Research Programs	93.273			1,827,883	78,331
Alcohol Research Programs	93.273	Johns Hopkins University	5R01AA02348305	(1,245)	-
Alcohol Research Programs	93.273	RTI International	1R01AA02704901A1	135,957	-
COVID-Alcohol Research Programs	93.273	State University Of New York	1R01AA02991401	47,114	-
Alcohol Research Programs	93.273	State University Of New York	5U10AA008401	1,206,136	-
Alcohol Research Programs	93.273	University of California, San Francisco	1R01AA031445-01A1	6,688	-
Alcohol Research Programs	93.273	University Of Iowa	1R01AA030914-01	46,357	-
Alcohol Research Programs	93.273	University Of Maryland	7R01AA02998902	30,461	-
Alcohol Research Programs	93.273	University of Missouri System	5R01AA02782403	106,509	-
Alcohol Research Programs	93.273	University Of North Carolina Chapel Hill	1R01AA030480-01	39,975	-
Drug Abuse and Addiction Research Programs	93.279			25,329,181	7,700,637
Drug Abuse and Addiction Research Programs	93.279	Brandeis University	2P30DA03577206A1	5,019	-
Drug Abuse and Addiction Research Programs	93.279	Children's Hospital Los Angeles	5U01DA03692607	641,516	-
Drug Abuse and Addiction Research Programs	93.279	George Washington University	5R01DA054751	225,064	-
COVID-Drug Abuse and Addiction Research Programs	93.279	Harvard Pilgrim Health Care	1R01DA05513101	67,211	-
Drug Abuse and Addiction Research Programs	93.279	Intra-Cellular Therapies Inc	1UG3DA04769901	463,768	-
Drug Abuse and Addiction Research Programs	93.279	Massachusetts General Hospital	5R24DA05198802	17,567	-
Drug Abuse and Addiction Research Programs	93.279	New York University	4UH3CA261067-02	29,394	-
COVID-Drug Abuse and Addiction Research Programs	93.279	New York University	5U24NS11384401	7,775	-

The accompanying notes are an integral part of this schedule

Washington University
Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity	Total	Passed to Sub-
	Listing Number		Identification Number	Expenditures	Recipients
Drug Abuse and Addiction Research Programs	93.270	Rissana, LLC	1R44DA055161-01	45,644	-
Drug Abuse and Addiction Research Programs	93.270	Saint Louis University	5R01DA04381105	29,667	-
Drug Abuse and Addiction Research Programs	93.270	The Miriam Hospital	5R25DA03719007	4,937	-
Drug Abuse and Addiction Research Programs	93.270	The Regents of the University of California	1U24DA05532501	92,310	-
Drug Abuse and Addiction Research Programs	93.270	The Regents of the University of California	5U24DA04112309	25,984	-
Drug Abuse and Addiction Research Programs	93.270	The Regents of the University of California	5U24DA04114708	118,782	-
Drug Abuse and Addiction Research Programs	93.270	The Regents of the University of California	5U01DA041089	26,202	-
Drug Abuse and Addiction Research Programs	93.270	University Of Arkansas	5R21DA05683502	64,717	-
Drug Abuse and Addiction Research Programs	93.270	University Of California Los Angeles	5R01DA05375202	898	-
Drug Abuse and Addiction Research Programs	93.270	University Of North Carolina Chapel Hill	5R01DA04787605	16,812	-
Drug Abuse and Addiction Research Programs	93.270	University of Washington	1R21DA05672501A1	45,406	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			7,965,527	238,000
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Albany Research Institute	5P41EB01878309	413,358	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Boston Children's Hospital	5R01EB03236602	198,109	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	5R01EB02925904	81,164	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	2R56EB029259-05	50,034	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Duke University	7R01EB02943102	33,130	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Georgia Institute Of Technology	1R01EB02985201	4,856	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Rice University	1R21EB033160-01	34,182	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	TetraImaging, LLC	5R43EB02640103	241,048	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Delaware	5R01EB02757703	111,116	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Illinois at Urbana-Champaign	5R01EB02865203	2,121	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Michigan	5R01EB02207508	19,914	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Texas Southwestern	7R01EB03008702	62,448	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Virginia	1R18EB035019-01	89,190	-
Minority Health and Health Disparities Research	93.307			3,542,442	367,790
Minority Health and Health Disparities Research	93.307	Michigan State University	1R01MD01805101	140,585	-
Minority Health and Health Disparities Research	93.307	Northwestern University	5R01MD01174904	(1,122)	-
Minority Health and Health Disparities Research	93.307	Rector & Visitors Of The University Of Virginia	5R01MD00770207	38,807	-
Minority Health and Health Disparities Research	93.307	University Of Maryland College Park	1R01MD01843701A1	40,936	-
Minority Health and Health Disparities Research	93.307	University Of North Carolina Chapel Hill	1R21MD01646701	34,025	-
Minority Health and Health Disparities Research	93.307	University Of North Carolina Chapel Hill	5R01MD015109-04	59,179	-
Trans-NIH Research Support	93.310			10,071,705	1,552,404
COVID-Trans-NIH Research Support	93.310			12,042	-
Trans-NIH Research Support	93.310	Duke University	3UCOD02337504\$1	27,019	-
Trans-NIH Research Support	93.310	Florida State University	5R01MD01740403	99,964	-
Trans-NIH Research Support	93.310	George Mason University	1OT2OD034479-01	49,812	-
Trans-NIH Research Support	93.310	George Mason University	5OT2OD03447902	85,128	-
Trans-NIH Research Support	93.310	Harvard University	5U01HG00753008	(6,181)	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	1UF1NS131791-01	58,687	-
Trans-NIH Research Support	93.310	Medical College Of Wisconsin	5U24HG010423-04	(23)	-
Trans-NIH Research Support	93.310	Regents Of The University Of Michigan	3U2CES03016404\$1	(488)	-
Trans-NIH Research Support	93.310	The Board Of Trustees Of The Leland Stanford Junior University	1U54HG01272301	43,254	-
Trans-NIH Research Support	93.310	The Board Of Trustees Of The Leland Stanford Junior University	5U54HG01272302	222,668	-
Trans-NIH Research Support	93.310	The Brigham And Women's Hospital Inc	5UH3OD02326807	63,119	-
Trans-NIH Research Support	93.310	The Regents of the University of California	5UM1HG011585	112,626	-
Trans-NIH Research Support	93.310	University of Connecticut	5U01HL15634903	5,124	-
Trans-NIH Research Support	93.310	University Of Florida	0T2OD033753-01	39,607	-
Trans-NIH Research Support	93.310	University of Nevada, Las Vegas	1U01OD03323901	1,294	-
Trans-NIH Research Support	93.310	University of Nevada, Las Vegas	8U01HD11525602	8,010	-
Trans-NIH Research Support	93.310	University Of North Carolina Chapel Hill	5U24DK116204	123,025	-
Trans-NIH Research Support	93.310	University of Rwanda	1UE5HL172181-01	15,157	-
Trans-NIH Research Support	93.310	University of South Florida	1OT2OD032720-01	177,903	-
Trans-NIH Research Support	93.310	University Of Wisconsin	5UH3OD023282	147,387	-
National Center for Advancing Translational Sciences	93.350			14,166,553	1,440,960
National Center for Advancing Translational Sciences	93.350	Altamira Therapeutics Inc	1R41TR00324401A1	68,379	-
National Center for Advancing Translational Sciences	93.350	Children's Hospital Corporation	5U01TR00262303	36,212	-
National Center for Advancing Translational Sciences	93.350	Dystonia Medical Research Foundation	U54TR001456	2,032	-
National Center for Advancing Translational Sciences	93.350	Harvard University	3UL1TR00254104\$2	(3,475)	-
National Center for Advancing Translational Sciences	93.350	Northwestern University	1U01TR00352801	240,049	-
National Center for Advancing Translational Sciences	93.350	Saint Louis Integrated Health Network	5U01TR003528-03	166,895	-
National Center for Advancing Translational Sciences	93.350	Seattle Children's Research Institute	1R21TR00405701	(4,203)	-
National Center for Advancing Translational Sciences	93.350	University of California	1R21TR00442201	25,896	-
National Center for Advancing Translational Sciences	93.350	University of Colorado Denver	5U24TR00230606	4,726	-
National Center for Advancing Translational Sciences	93.350	University Of Iowa	5R21TR00341002	5,234	-
National Center for Advancing Translational Sciences	93.350	University Of North Carolina Chapel Hill	7R01TR00386002	63,397	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh Medical Center	1U01TR00371901A1	12,242	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh Medical Center	5U01TR00371902	21,262	-
National Center for Advancing Translational Sciences	93.350	Virginia Commonwealth University	5R21TR00318402	189	-
Research Infrastructure Programs	93.351			3,071,002	-
Research Infrastructure Programs	93.351	Cornell University	5P40OD010964	103,650	-
Construction Support	93.352			7,972,413	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353			7,624,940	115,995
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Children's Hospital Of Philadelphia (The)	1U54CA23256801	2,214	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Duke University	1U2CCA2325401	95,066	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity	Total	Passed to Sub-
	Listing Number		Identification Number	Expenditures	Recipients
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Fred Hutchinson Cancer Center	6UM1CA15496712	39,813	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Stanford University	1R01CA28389601	79,263	-
Nursing Research	93.361			1,053,610	472,702
COVID-Nursing Research	93.361			490,429	102,638
Nursing Research	93.361	Emory University	1K23NR020037	243	-
Nursing Research	93.361	Trustees Of Columbia University In the City Of New York	2R01NR01694107	56,130	-
Nursing Research	93.361	University Of Alabama Birmingham	1R01NR01941701A1	34,692	-
Nursing Research	93.361	University Of Alabama Birmingham	5R01NR020523-02	52,907	-
Nursing Research	93.361	University of Houston	1R21NR020379	97,388	-
Cancer Cause and Prevention Research	93.393			12,466,477	1,415,647
Cancer Cause and Prevention Research	93.393	Arizona State University	2U01CA19790206	72,543	-
Cancer Cause and Prevention Research	93.393	Baylor College of Medicine	2U19CA20365407	109,446	-
Cancer Cause and Prevention Research	93.393	Baylor University	5U19CA20365405	32	-
Cancer Cause and Prevention Research	93.393	Duke University	1R35CA26393401	12,463	-
Cancer Cause and Prevention Research	93.393	Eastern Virginia Medical School	5R37CA245716-03	100,214	-
Cancer Cause and Prevention Research	93.393	Kaiser Permanente	1R01CA26232501	(13,910)	-
Cancer Cause and Prevention Research	93.393	Lawrence Berkeley National Laboratory	2P01CA092584-21	64,325	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5R01CA23361004	134,645	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5U01CA19556808	92,698	-
Cancer Cause and Prevention Research	93.393	Medical University of South Carolina	1R01CA28216501	54,600	-
Cancer Cause and Prevention Research	93.393	Medical University of South Carolina	5R37CA269385-02	152,797	14,018
Cancer Cause and Prevention Research	93.393	Northwestern University	5R01CA218436	13,202	-
Cancer Cause and Prevention Research	93.393	Research Institute at Nationwide Children's Hospital	1R01CA284073-01	13,659	-
Cancer Cause and Prevention Research	93.393	Rockefeller University	5P01CA196539	332,854	-
Cancer Cause and Prevention Research	93.393	St. Jude Children's Research Hospital	5R37CA27621502	217,152	-
Cancer Cause and Prevention Research	93.393	The Hospital for Sick Children	5R01CA2511203	21,089	-
Cancer Cause and Prevention Research	93.393	Trustees Of The University Of Pennsylvania	5R01CA17490410	7,042	-
Cancer Cause and Prevention Research	93.393	University of Colorado	1R01CA279953-01	205,538	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Charlotte	3U01CA23550703S1	84,979	-
Cancer Cause and Prevention Research	93.393	University Of North Carolina Chapel Hill	1R01CA276408-01A1	46,187	-
Cancer Cause and Prevention Research	93.393	University Of North Carolina Chapel Hill	5P01CA22559704	137,004	-
Cancer Cause and Prevention Research	93.393	University Of North Carolina Chapel Hill	7R03CA27248503	7,684	-
Cancer Cause and Prevention Research	93.393	University Of Texas MD Anderson Cancer Center	5R01CA22564703	367	-
Cancer Cause and Prevention Research	93.393	University of Utah	5U01CA206110	204,007	-
Cancer Cause and Prevention Research	93.393	University of Washington	7R01CA26232503	75,362	-
Cancer Cause and Prevention Research	93.393	Vanderbilt University Medical Center	5R01CA22500506	9,011	-
Cancer Cause and Prevention Research	93.393	Wake Forest University	5R01CA22607806	237,070	-
Cancer Detection and Diagnosis Research	93.394			16,340,924	3,233,974
Cancer Detection and Diagnosis Research	93.394	Acoustic Range Estimates LLC	5R44CA24376403	64,985	-
Cancer Detection and Diagnosis Research	93.394	Indiana University	1U24CA27962901A1	77,759	-
Cancer Detection and Diagnosis Research	93.394	Memorial Sloan Kettering Cancer Center	5R01CA24423303	101,353	-
Cancer Detection and Diagnosis Research	93.394	New York University	5U24CA210972	(102)	-
Cancer Detection and Diagnosis Research	93.394	Princeton University	1U24CA26402701	(2,865)	-
Cancer Detection and Diagnosis Research	93.394	Regents Of The University Of Michigan	5R01CA240706	21,725	-
Cancer Detection and Diagnosis Research	93.394	Sarya LLC	1R42CA25779701	259,825	-
Cancer Detection and Diagnosis Research	93.394	St. Jude Children's Research Hospital	4U01CA246570-02	6,854	-
Cancer Detection and Diagnosis Research	93.394	Texas A&M University	1R21CA26909902	76,408	-
Cancer Detection and Diagnosis Research	93.394	Trustees Of The University Of Pennsylvania	5R01CA25871704	70,249	-
Cancer Detection and Diagnosis Research	93.394	University Of California Los Angeles	5R01CA24630403	10,659	-
Cancer Detection and Diagnosis Research	93.394	University Of Florida	1R01CA27781701A1	77,890	-
Cancer Detection and Diagnosis Research	93.394	University Of Miami	5U01CA233363	44,703	-
Cancer Detection and Diagnosis Research	93.394	University Of San Francisco	5R01CA21214805	(3,600)	-
Cancer Detection and Diagnosis Research	93.394	University of South Florida	1R01CA240319-01A1	17,084	-
Cancer Detection and Diagnosis Research	93.394	University of Texas Southwestern	R01CA260855	87,643	-
Cancer Treatment Research	93.395			12,391,161	1,081,525
Cancer Treatment Research	93.395	Accuronix Therapeutics	2R41CA23985302A1	34,489	-
Cancer Treatment Research	93.395	Accuronix Therapeutics	5R42CA23985303	(6,458)	-
Cancer Treatment Research	93.395	Albert Einstein College of Medicine	7R01CA235622-05	151,963	-
Cancer Treatment Research	93.395	American College of Radiology	1U24CA180803	27,307	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia (The)	5R01CA21199602	2,054	-
Cancer Treatment Research	93.395	Duke University	3UM1CA18670405S1	213,679	-
Cancer Treatment Research	93.395	ECOG-ACRIN Cancer Research Group	5U01CA18082008	6,644	-
Cancer Treatment Research	93.395	ECOG-ACRIN Cancer Research Group	5U10CA18082009	18,445	-
Cancer Treatment Research	93.395	ECOG-ACRIN Cancer Research Group	PDS137629	3,864	-
Cancer Treatment Research	93.395	George Washington University	1R01CA27590401	321,528	-
Cancer Treatment Research	93.395	Memorial Sloan Kettering Cancer Center	5U01CA23844402	40,063	-
Cancer Treatment Research	93.395	NRG Oncology Foundation Inc	U10CA180868	56,371	8,433
Cancer Treatment Research	93.395	NRG Oncology Foundation Inc	5U10CA18086809	15,006	-
Cancer Treatment Research	93.395	NRG Oncology Foundation Inc	U10CA180868-10	7,169	-
Cancer Treatment Research	93.395	Public Health Institute	3U10CA180886-10S1	283	-
Cancer Treatment Research	93.395	Public Health Institute	5UM1CA22882305	909	-
Cancer Treatment Research	93.395	Public Health Institute	7U10CA18088608	(1,462)	-
Cancer Treatment Research	93.395	Public Health Institute	7UM1CA22882304	85,176	-
Cancer Treatment Research	93.395	Public Health Institute	U10CA180886	172,989	-
Cancer Treatment Research	93.395	Regents Of The University Of Minnesota	P01CA111412	79,289	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity	Total	Passed to Sub-
	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Cancer Treatment Research	93.395	Saint Louis University	1R21CA263428-01A1	13,192	-
Cancer Treatment Research	93.395	St. Jude Children's Research Hospital	1U01CA24657001A1	3,884	-
Cancer Treatment Research	93.395	The Brigham And Women's Hospital Inc	3U10CA180821-10S1	33,292	-
Cancer Treatment Research	93.395	The Brigham And Women's Hospital Inc	5U01CA180821	117,017	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia (The)	U10CA180886	(5,395)	-
Cancer Treatment Research	93.395	The Emmes Company, LLC	5UM1CA121947	346,927	-
Cancer Treatment Research	93.395	University Of Cincinnati	7UG1CA2333805	148,732	-
Cancer Treatment Research	93.395	University Of Miami	7R01CA25308602	55,776	-
Cancer Treatment Research	93.395	University Of Rochester	1R01CA21489001A1	(8,164)	-
Cancer Treatment Research	93.395	University Of Texas MD Anderson Cancer Center	5R01CA23562204	(9,533)	-
Cancer Treatment Research	93.395	Yale University	UM1CA186689	438,335	-
Cancer Biology Research	93.396			12,762,830	567,346
Cancer Biology Research	93.396	Case Western Reserve University	1P01CA245705	459,641	-
Cancer Biology Research	93.396	Coriell Institute for Medical Research	5R01CA24423602	254,605	-
Cancer Biology Research	93.396	Ohio State University	5P01CA100730	681,201	-
Cancer Biology Research	93.396	Pennsylvania State University	5R21CA274265-02	96,913	-
Cancer Biology Research	93.396	Saint Louis University	1R37CA265877-01A1	59,759	-
Cancer Biology Research	93.396	Saint Louis University	5R37CA26587702	44,580	-
Cancer Biology Research	93.396	The Board Of Trustees Of The Leland Stanford Junior University	5R01CA25838403	268,402	-
Cancer Biology Research	93.396	The Regents of the University of California	1U01CA26703101	33	-
Cancer Biology Research	93.396	The Regents of the University of California	1U01CA26703102	43,869	-
Cancer Biology Research	93.396	The Regents of the University of California	5U01CA26703103	120,047	-
Cancer Biology Research	93.396	University of California, San Francisco	7R01CA23455305	114,895	-
Cancer Center Support Grants	93.397			13,473,513	1,136,545
Cancer Center Support Grants	93.397	Northwestern University	5P50CA221747-05	7,245	-
Cancer Center Support Grants	93.397	St. Jude Children's Research Hospital	3P30CA02176544S2	14,844	-
Cancer Center Support Grants	93.397	University Of Alabama Birmingham	5R01MD010441-05	8,306	-
Cancer Center Support Grants	93.397	University Of North Carolina Chapel Hill	1P50CA257911-01A1	80,533	-
Cancer Research Manpower	93.398			5,515,144	-
Cancer Control	93.399			165,560	-
Cancer Control	93.399	University of Michigan	5UG1CA242632	15,523	-
Cardiovascular Diseases Research	93.837			33,347,943	3,403,543
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	1R01HL16456101	34,141	-
Cardiovascular Diseases Research	93.837	Cedars Sinai Medical Center	5R01HL14994604	4,073	-
Cardiovascular Diseases Research	93.837	Clemson University	2R01HL133662-05A1	130,936	-
Cardiovascular Diseases Research	93.837	Duke University	1OT2HL156812-01	4,481	-
Cardiovascular Diseases Research	93.837	Duke University	1R01HL15539601A1	13,056	-
Cardiovascular Diseases Research	93.837	Emory University	5R01HL12239207	(24)	-
Cardiovascular Diseases Research	93.837	HealthCore Inc	U24HL135691	(11,461)	-
Cardiovascular Diseases Research	93.837	Indiana University	1R01HL15921601A1	11,181	-
COVID-Cardiovascular Diseases Research	93.837	Johns Hopkins University	10T2HL15681201	7,200	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5U01HL09681212	429,803	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U24HL138660	171	-
Cardiovascular Diseases Research	93.837	New England Research Institutes	5U24HL135691	7,046	-
Cardiovascular Diseases Research	93.837	New York University	2U01HL09681213	191,194	-
Cardiovascular Diseases Research	93.837	New York University	5R01HL04509532	361,492	-
Cardiovascular Diseases Research	93.837	New York University	5R01HL147811	27,723	-
Cardiovascular Diseases Research	93.837	New York University	5R01HL157091-03	46,068	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL14858104	24,452	-
Cardiovascular Diseases Research	93.837	Rector & Visitors Of The University Of Virginia	5P01HL12084009	607,089	-
Cardiovascular Diseases Research	93.837	Regents Of The University Of Michigan	4UH3HL15913402	23,563	-
Cardiovascular Diseases Research	93.837	Saint Louis University	1R01HL160553-01A1	72,128	-
Cardiovascular Diseases Research	93.837	Saint Louis University	R56HL165199	25,874	-
Cardiovascular Diseases Research	93.837	State University Of New York	1R01HL16662801A1	155,559	-
Cardiovascular Diseases Research	93.837	State University Of New York	5U01HL13155205	3,374	-
Cardiovascular Diseases Research	93.837	Trustees Of The University Of Pennsylvania	5R34HL14692703	(1,681)	-
Cardiovascular Diseases Research	93.837	UNandUP, LLC (UN&UP)	2R44HL147745-02A1	27,115	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	2R01HL12033807A1	34,312	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5R01HL12033809	36,686	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5R01HL148462-04	37,844	-
Cardiovascular Diseases Research	93.837	University Of California Davis	5UH3HL1418002	2,392	-
Cardiovascular Diseases Research	93.837	University Of Iowa	1R01HL171624-01	23,479	-
Cardiovascular Diseases Research	93.837	University Of North Carolina Chapel Hill	5R01HL15725502	25,750	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania School of Medicine	5R01HL14827203	64,336	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Medical Center	7R01HL15946102	56,243	-
Cardiovascular Diseases Research	93.837	University of Texas Health Science Center at Houston	5R01HL14502503	37,264	-
Cardiovascular Diseases Research	93.837	University of Texas Health Science Center at Houston	5R01HL14686003	30,392	-
Cardiovascular Diseases Research	93.837	University of Washington	5P01HL15132803	398,116	-
Cardiovascular Diseases Research	93.837	University of Washington	5R01HL16182902	31,625	-
Lung Diseases Research	93.838			9,196,700	581,530
Lung Diseases Research	93.838	Boston University	1P01HL170952-01	2,380	-
Lung Diseases Research	93.838	Children's Hospital Of Philadelphia (The)	5R01HL14805404	5,430	-
Lung Diseases Research	93.838	Cornell University	1UG3HL15494401A1	8,258	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	5UH3HL14701104	11,107	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	6UH3HL14701103	(14,014)	-

The accompanying notes are an integral part of this schedule

Washington University
Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity	Total	Passed to Sub-Recipients
	Listing Number	Pass Through Entity	Identification Number	Expenditures	
Lung Diseases Research	93.838	Northwestern University	5P01HL15499803	54,535	-
Lung Diseases Research	93.838	Ohio State University	SPC-1000012331 / GR130859	629,527	-
Lung Diseases Research	93.838	Rector & Visitors Of The University Of Virginia	R01HL157407	27,422	-
Lung Diseases Research	93.838	Regents Of The University Of Michigan	1R01HL15351901	865	-
Lung Diseases Research	93.838	Regents Of The University Of Michigan	5R01HL14726104	98,520	-
Lung Diseases Research	93.838	The Brigham And Women's Hospital Inc	5U01HL14600204	74,216	-
Lung Diseases Research	93.838	The Regents of the University of California	OT2HL16184701	244,754	-
COVID-Lung Diseases Research	93.838	Trustees Of Columbia University In the City Of New York	RT122312021757166178	28,335	-
Lung Diseases Research	93.838	Trustees Of The University Of Pennsylvania	4UH3HL15230502	8,179	-
Lung Diseases Research	93.838	Trustees Of The University Of Pennsylvania	5U01HL148857	131,474	-
Lung Diseases Research	93.838	University of Alabama	5R01HL147603-04	13,860	-
Lung Diseases Research	93.838	University Of Arizona	5U01HL13004506	320,385	20,677
Lung Diseases Research	93.838	University Of Arizona	R25-HL126140	7,933	-
Lung Diseases Research	93.838	University Of Cincinnati	1R01HL16226101A1	6,174	-
Lung Diseases Research	93.838	University of Colorado Denver	5P01HL15296104	14,920	-
Lung Diseases Research	93.838	University Of North Carolina Chapel Hill	5U24HL13899806	299,371	-
Lung Diseases Research	93.838	University Of North Carolina Chapel Hill	5U54HL096458	71,313	-
Lung Diseases Research	93.838	University of Pittsburgh	5R01HL142084-04	11,958	-
Lung Diseases Research	93.838	University of Pittsburgh	1R01HL166953-01A1	15,008	-
Lung Diseases Research	93.838	University of Washington	1R03HL16025101A1	13,497	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	1U01HL168412-01	16,755	-
Lung Diseases Research	93.838	Wayne State University	5R01HL148247	59,838	-
Lung Diseases Research	93.838	Weill Medical College of Cornell University	4R33 HL15301102	133,892	-
Blood Diseases and Resources Research	93.839			9,272,885	659,006
Blood Diseases and Resources Research	93.839	Emory University	5UG3HL148560	69,921	-
Blood Diseases and Resources Research	93.839	Icahn School Of Medicine At Mount Sinai	1U01HL16703601	80,962	-
Blood Diseases and Resources Research	93.839	Medical College Of Wisconsin	1U01HL15985001	(5,258)	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	1U24HL15756001A1	16	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL138660	17,319	-
Blood Diseases and Resources Research	93.839	Nemours Foundation	7U01HL159850-03	15,158	-
Blood Diseases and Resources Research	93.839	New York University	1UG3HL15579801A1	5,497	-
Blood Diseases and Resources Research	93.839	New York University	4UG3HL15579802	55,079	-
Blood Diseases and Resources Research	93.839	Senseion Therapeutics, Inc.	1R44HL169181-01A1	4,548	-
Blood Diseases and Resources Research	93.839	University Of Alabama Birmingham	1UG3HL157401-01A1	2,634	-
Blood Diseases and Resources Research	93.839	University of Colorado Denver	R33HL141794	98,966	-
Blood Diseases and Resources Research	93.839	University Of Maryland	7UH3HL14319205	41,487	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5P01HL14445704	536,111	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5R01HL06883515	11,284	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840			4,348,631	1,015,728
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Infectious Diseases Research Collaboration	3UH3HL154501-04S1	9,018	-
COVID-Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	New York University	0T2HL156812	960	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Universidad Peruana Cayetano Heredia	5UGHL15237102	169,927	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Universidad Peruana Cayetano Heredia	5UGHL15237103	16	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	University of Abuja	1UG3HL154498-04	41,038	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	University of Abuja	4UG3HL15238103	56,224	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Vanderbilt University	1OT2HL15681201	131,493	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846			14,659,520	1,077,317
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Biorestorative Therapies Inc	1R41AR0793401	2,730	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Boston University	5R01AR07442804	3,934	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Of Philadelphia (The)	1R01AR07982201	4,947	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Cleveland Clinic Lerner College of Medicine	3R01AR07542204S1	34,131	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Hebrew Rehabilitation Center	5R01AR07534602	16,307	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Icahn School Of Medicine At Mount Sinai	5R01AR07700703	24,017	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Indiana University	5R01AR07647702	10,502	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR07601304	17,871	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northeast Ohio Medical University	5R01AR07776202	(762)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents Of The University Of Michigan	5R01AR07936702	139,119	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Rush University Medical Center Obligated Group	5P30AR079206-02	15,053	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	St. Louis University	A01883-17749	255,095	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Brigham And Women's Hospital Inc	5R01AR05555712	21,197	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Brigham And Women's Hospital Inc	U01AR070498	1,061	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees Of Columbia University In the City Of New York	5R01AR06294709	121,460	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of California Irvine	1R01AR078340	62,708	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Pittsburgh	5R01AR07614604	51,620	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Texas Southwestern Medical Center	1R01AR078311-01A1	18,888	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Vanderbilt University	5R01AR06084608	110,592	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			51,080,550	6,136,962
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Acetaminophen Toxicity Diagnostics LLC	5SB1DK079387	2,876	-
COVID-Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Albert Einstein College of Medicine	P30DK020541	171,644	61,525
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Ann & Robert H. Lurie Children's Hospital of Chicago	U01DK127905	5,977	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK1525504	(22,027)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beckman Research Institute of the City of Hope	U24DK104162-09	212,268	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	U01DK094157	141,156	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars Sinai Medical Center	5U01DK06241320	(1,166)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Of Philadelphia (The)	5R01DK09783007	30,361	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity	Total	Passed to Sub-
	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Kansas City	5U01DK06614322	646	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cleveland Clinic Lerner College of Medicine	5R01DK12279002	295,300	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824610	29,968	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Georgia Institute Of Technology	R01DK133702	97,557	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School Of Medicine At Mount Sinai	1R01DK135470-01	6,735	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Johns Hopkins University	5R01DK128900-04	5,389	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	McGill University	5R01DK11073703	950	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	5U01DK10086609	24,848	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	NorthShore University HealthSystem	2R01DK100368-06A1	15,918	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute For Research And Education	5R01DK125646	38,918	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	1R01DK134629-01	36,474	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	2R01DK09221709	71,101	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5R01DK12574902	6,825	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Oregon Health & Science University	5R01DK11549505	104	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	PlatformSTL	1R41DK135161-01	67,555	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	PlatformSTL	5R42DK12025303	25,267	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rutgers The State University Of NJ	1R01DK13288501	68,218	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Saint Louis University	1R01DK13453102	18,179	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion Therapeutics, Inc.	2R44DK12159802A1	109,369	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion, LLC	5R44DK12660003	143,373	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Board Of Trustees Of The Leland Stanford Junior University	1K12DK13399501	160,233	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Brigham And Women's Hospital Inc	1U24DK135157-01	127,774	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Children's Mercy Hospital	5U01DK06614320	4,106	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Alabama Birmingham	5P30DK07933715	3,165	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Alabama Birmingham	5R01DK12749702	777	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of California, Los Angeles	5U01DK122013-03	1,610	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of California, San Francisco	5R01DK11598703	10,615	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of California, San Francisco	5R01DK12279704	18,056	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Chicago	5U54DK11861205	214,177	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Colorado Denver	1U01DK12919102	9,135	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Florida	7R01DK114485-05	2,530	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	3U01DK108334-08S1	124	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	3U01DK10833490S1	2,239	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	5R01DK11875204	17,779	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	5U01DK10833407	43,015	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Kansas Medical Center	1R01DK134737-01	39,415	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Kansas Medical Center	1R56DK12923401	423,514	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Maryland, Baltimore	5U24DK126110	77,365	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Tennessee	7R01DK12574904	2,971	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Wisconsin	1U24DK127726-01	22,422	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	1R01DK11921201	(1,335)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Wake Forest University	5R01DK12887104	33,649	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Weill Medical College of Cornell University	5R01DK12581702	3,961	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			54,073,467	5,860,049
COVID-Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			68,073	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Albany Research Institute	7U01NS10891603	116,776	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Barrow Neurological Institute	1OT2NS13693901	195,553	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	1R21NS12721101A1	3,190	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS118146604	14,848	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R21NS12721102	10,231	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	7R01NS118146603	33,249	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	California Institute Of Technology	1U01NS12656201	248,149	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's National Health System	5R01NS11229405	27,521	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cleveland Clinic Foundation	U01NS116776	44,930	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	5R01NS1158803	399	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54NS11602510	354,725	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	FreeFlow Medical Device LLC	5R42NS10370404	131,439	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Harvard University	1U2CNS13241501	893,786	403,663
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Harvard University	3U2CNS132415-01S1	271,394	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hugo W Moser Research Institute at Kennedy Krieger Inc	2K12NS09848206	466,541	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School Of Medicine At Mount Sinai	5R01NS12744202	27,586	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5R01NS10629202	571	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5U01NS1167803	50,353	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS117609-03	45,915	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS1102905	61,995	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	7R01NS112712-04	39,847	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	1U01NS128612-01	114,043	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5U01NS128612-02	213,976	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Medical University of South Carolina	3OT2NS129366-01S1	24,307	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Minnetronix	5R44NS11024703	(19,649)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	2R42NS11364201	111,909	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	5R42NS11518403	57,528	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5R01NS12586302	59,715	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5U01NS11385102	32,388	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Nous Imaging Inc	1R44NS12952101	104,447	-

The accompanying notes are an integral part of this schedule

Washington University
Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity	Total	Passed to Sub-
	Listing Number		Identification Number	Expenditures	
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	1R01NS12368701	12,276	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Oregon Health & Science University	1015486_WUSTL	158,801	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Phoenix Nest Inc	2U44NS080906105	(24)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rector & Visitors Of The University Of Virginia	5R01NS09011804	(29)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rector & Visitors Of The University Of Virginia	5R01NS12567702	250,949	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents Of The University Of Colorado	1U01NS11431201A1	12,420	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents Of The University Of Michigan	1RF1NS127606-01	20,637	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Research Foundation of the City University of New York	5R01NS11801203	17,529	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers The State University Of NJ	U24NS095914	183,110	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Saint Louis University	5R01NS11428904	17,437	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Jude Children's Research Hospital	5R01NS12111403	436,339	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Louis College of Pharmacy	1R34NS126036-01	1,124	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Louis College of Pharmacy	5R01NS12307002	38,546	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Board Of Trustees Of The Leland Stanford Junior University	5R01NS12172002	8,514	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute Inc	1U24NS132940-01	61,035	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In the City Of New York	1R01NS11082601A1	(291)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In the City Of New York	5R01NS11082603	55,097	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania	1U19NS11045601A1	(13,204)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania	2-RF1-NS-103873-05	55,326	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania	582577	57,415	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania	5R01NS11586902S1	(10,984)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University Of Pennsylvania	5U19NS110456	1,030,624	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	UNandUP, LLC (UN&UP)	1R44NS12260401	5,413	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	UNandUP, LLC (UN&UP)	1R44NS12260501	35,253	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Arizona	5R01NS10629805	8,963	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Arizona	5R01NS12710802	83,476	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California Davis	75N94020D000002	17,673	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California Irvine	1R01NS123287-01A1	199,305	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California, San Francisco	1U01NS12083601	(1,503)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California, San Francisco	1U54NS12398501	210,196	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California, San Francisco	5R01NS058721-13	43,054	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California, San Francisco	5R01NS111166-03	19,337	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California, San Francisco	5U01NS12083603	183,629	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of California, San Francisco	5U54NS123985-03	624,763	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Chicago	5R01NS11626202	139,808	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1UG3NS119702-01A1	6,039	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS10228901A1	9,437	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS11072801	289	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS11077201	33,267	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1U01NS117450-01A1	34,898	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	1UG3NS125023-01A1	10,007	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	5U01NS09904302	42,108	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	5U01NS10651302	14,875	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Cincinnati	7U01NS10069903	3,029	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Connecticut	5R01NS10263306	(224)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Florida	5U01NS11956203	5,931	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Illinois Chicago	1R01NS127403-01A1	145,622	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Miami	1U24NS12085801	99,665	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of North Carolina Chapel Hill	5R01NS12223002	154,253	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Pittsburgh	1R01NS129613-01A1	11,842	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Southern California	5R01NS093446724	202,475	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Southern California	5UH3NS11692904	128,695	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Texas Medical Branch	1U3NS128397-01A1	2,157	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Utah	5U01NS107486	50,352	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Washington	1U01NS128537-01	93,080	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Washington	5R01NS091618-09	64,589	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University	5UH3NS116218-03	58,200	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Virginia Commonwealth University	1U01NS12497401A1	39,897	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Weill Medical College of Cornell University	1R01NS13011301	38,296	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Weill Medical College of Cornell University	5R01NS11199703	192,231	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1UG3NS130228-01	52,598	-
Allergy and Infectious Diseases Research	93.855			75,656,694	12,291,739
COVID-Allergy and Infectious Diseases Research	93.855			755,817	-
Allergy and Infectious Diseases Research	93.855	Albert Einstein College of Medicine	5R01AI15819403	400,517	-
Allergy and Infectious Diseases Research	93.855	Baylor College of Medicine	2R01AI03295630	(27)	-
Allergy and Infectious Diseases Research	93.855	Baylor College of Medicine	5U19AI157981-03	10,654	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	5U19AI6789102	294,226	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute At Virginia Mason	UM1AI109565	241,329	-
Allergy and Infectious Diseases Research	93.855	Big Eye Diagnostics	1R43AI17245901	7,913	-
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	1R56AI16301301	656	-
Allergy and Infectious Diseases Research	93.855	Boston University	1R2AI15623601	14,583	-
Allergy and Infectious Diseases Research	93.855	Cedars Sinai Medical Center	1U01AI17042402	53,689	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation	5R01AI17314202	8,132	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation	5U01AI12661406	152,029	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Los Angeles	1U01AI12661201A1	3,843	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity	Total	Passed to Sub-Recipients
	Listing Number	Pass Through Entity	Identification Number	Expenditures	
Allergy and Infectious Diseases Research	93.855	Children's Hospital Of Philadelphia (The)	5R01AI17151402	187,320	-
Allergy and Infectious Diseases Research	93.855	Cleveland Clinic Lerner College of Medicine	7R01AI12777406	2,252	-
Allergy and Infectious Diseases Research	93.855	Duke University	7R01-AI125045-08	(25)	-
Allergy and Infectious Diseases Research	93.855	Duke University	5U01-AI163065-03	60,421	-
Allergy and Infectious Diseases Research	93.855	Duke University	5R01AI14582805	254,952	-
Allergy and Infectious Diseases Research	93.855	Duke University	5U01AI16309903	56,629	-
Allergy and Infectious Diseases Research	93.855	Emory University	1R21AI173471-01A1	33,341	-
Allergy and Infectious Diseases Research	93.855	Emory University	1U01AI15074701	(512)	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U01AI15074704	241,377	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI11048310	178,639	-
Allergy and Infectious Diseases Research	93.855	Family Health International	UM1AI068619	86,313	-
Allergy and Infectious Diseases Research	93.855	Fimbrion Therapeutics Inc	1R43AI17255901A1	85,983	-
Allergy and Infectious Diseases Research	93.855	Fimbrion Therapeutics Inc	5R44AI14983304	323,919	-
Allergy and Infectious Diseases Research	93.855	Florida State University	5R01AI173416-03	14,373	-
Allergy and Infectious Diseases Research	93.855	Florida State University	5R21AI178556-03	23,313	-
Allergy and Infectious Diseases Research	93.855	Forward Defense LLC	1R41AI16713701A1	3,976	-
Allergy and Infectious Diseases Research	93.855	Fox Chase Cancer Center	1R56AI15096501A1	4,768	-
Allergy and Infectious Diseases Research	93.855	Fox Chase Cancer Center	1R56AI16808701A1	239,664	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	1P01AI172531-01	517,195	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	1R01AI168178-01	167,550	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	5R01AI16817802	281,405	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine At Mount Sinai	5R21AI16704703	3,373	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2P30AI09418911	64,127	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U19AI142790	499,722	-
Allergy and Infectious Diseases Research	93.855	Los Angeles Biomedical Research Institute	5U01AI11640005	67,007	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	1U01AI16308601	28	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI16308602	150,066	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI16308603	9,469	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI16308603 - 239761	28,981	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01AI12661006	8,589	-
Allergy and Infectious Diseases Research	93.855	MicroBiotix Inc	1R41AI16510201A1	62,610	-
Allergy and Infectious Diseases Research	93.855	National Children's Research Centre	5U01AI155300-03	33,295	-
Allergy and Infectious Diseases Research	93.855	Northwestern University	5P30AI11794310	55,416	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University	5R01AI13218605	581	-
Allergy and Infectious Diseases Research	93.855	Regents Of The University Of Colorado	5R01AI14143605	179,794	-
Allergy and Infectious Diseases Research	93.855	Regents Of The University Of Michigan	2R01AI11262606A1	237,397	-
Allergy and Infectious Diseases Research	93.855	Regents Of The University Of Michigan	2R01AI13467805	232,583	-
Allergy and Infectious Diseases Research	93.855	Regents Of The University Of Michigan	5U54AI17066002	194,065	-
Allergy and Infectious Diseases Research	93.855	Saint Louis University	1R01AI13019001A1	(47)	-
Allergy and Infectious Diseases Research	93.855	Saint Louis University	5R01AI13019002	68,970	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	1U19AI17144301	244,500	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5U19AI17144302	165,301	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Hospital	5U01AI144616	169,268	-
Allergy and Infectious Diseases Research	93.855	Temple University	1UM1AI1164568-02	494,049	-
Allergy and Infectious Diseases Research	93.855	Texas Tech University System	1R15AI15674601A1	21,107	-
Allergy and Infectious Diseases Research	93.855	The Board Of Trustees Of The Leland Stanford Junior University	1R01AI178298-01A1	25,880	-
Allergy and Infectious Diseases Research	93.855	The Board Of Trustees Of The Leland Stanford Junior University	5U19AI16448408	149,791	-
Allergy and Infectious Diseases Research	93.855	The Jackson Laboratory	5U19AI14273305	109,639	-
Allergy and Infectious Diseases Research	93.855	The Regents of the University of California	1R01AI16989201A1	220,351	-
Allergy and Infectious Diseases Research	93.855	The Regents of the University of California	5R01AI11463508	15,052	-
Allergy and Infectious Diseases Research	93.855	The Regents of the University of California	7R21AI15204902	15,892	-
Allergy and Infectious Diseases Research	93.855	Thomas Jefferson University	5R01AI16584002	42,648	-
Allergy and Infectious Diseases Research	93.855	Trustees Of The University Of Pennsylvania	1R01AI18004701	86,108	-
Allergy and Infectious Diseases Research	93.855	Trustees Of The University Of Pennsylvania	1R01AI18100701	59,111	-
Allergy and Infectious Diseases Research	93.855	Trustees Of The University Of Pennsylvania	5R01AI14053905	99,220	-
Allergy and Infectious Diseases Research	93.855	University Of Alabama Birmingham	5U19AI14275905	119,684	-
Allergy and Infectious Diseases Research	93.855	University Of Alabama Birmingham	5U54AI15022503	5,209	-
Allergy and Infectious Diseases Research	93.855	University Of Alabama Birmingham	5U54AI15022504	9,856	-
Allergy and Infectious Diseases Research	93.855	University Of Arizona	2R01AI12994506	122,411	-
Allergy and Infectious Diseases Research	93.855	University of Calgary	5R01AI16532702	99,942	-
Allergy and Infectious Diseases Research	93.855	University Of California Los Angeles	2UM1AI06863615	351,461	-
Allergy and Infectious Diseases Research	93.855	University Of California Los Angeles	5UM1AI06863616	59,050	-
Allergy and Infectious Diseases Research	93.855	University of California, San Francisco	1P01AI15539301A1	325,418	-
Allergy and Infectious Diseases Research	93.855	University of California, San Francisco	5P01AI155393-03	184,994	-
Allergy and Infectious Diseases Research	93.855	University of California, Santa Barbara	5R21AI16448302	160,188	-
Allergy and Infectious Diseases Research	93.855	University Of Florida	5R01AI14147805	5,084	-
Allergy and Infectious Diseases Research	93.855	University of Georgia Research Foundation	1R01AI173416-01A1	20,794	-
Allergy and Infectious Diseases Research	93.855	University of Georgia Research Foundation	R21AI178556	27,346	-
Allergy and Infectious Diseases Research	93.855	University Of Kentucky	5R01AI14075805	107,143	-
Allergy and Infectious Diseases Research	93.855	University Of Louisville	1R01AI3967101A1	1,129	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R01AI165519-01A1	18,101	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R01AI178378-01	60,173	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R21AI163606-02	17	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	1R56AI17192001	208,887	-
Allergy and Infectious Diseases Research	93.855	University Of Pittsburgh	5R01AI14266205	9,582	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity	Total	Passed to Sub-
	Listing Number	Pass Through Entity	Identification Number	Expenditures	Recipients
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh School of Medicine	5R01AI15021403	123,779	-
Allergy and Infectious Diseases Research	93.855	University of Texas Medical Branch	5R01AI14635302	226,432	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern	5U19AI142784	738,006	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01AI14529605	209,006	-
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	1R01AI15067801	349,614	-
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	1UM1AI16004001	221,768	-
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	1UM1AI16004002	382,567	-
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5P01AI13213205	20,033	-
Allergy and Infectious Diseases Research	93.855	University Of Wisconsin	5R01AI15313004	126,191	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5UM1AI14845204	20,421	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5UM1AI14845205	34,148	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	1R01AI17215601	399,512	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	3UM1AI14845203S3	989,578	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06861912	11,975	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI069439	696,610	-
COVID-Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	UM1AI068619	(6,834)	-
Allergy and Infectious Diseases Research	93.855	VaxNewMo, LLC	1R41AI16707801	97,660	-
Allergy and Infectious Diseases Research	93.855	VaxNewMo, LLC	1R42AI165116	153,466	-
Allergy and Infectious Diseases Research	93.855	Washington State University	5U01AI5179905	180,939	-
Allergy and Infectious Diseases Research	93.855	Weill Medical College of Cornell University	5U01AI095608-13	481,689	-
Biomedical Research and Research Training	93.850			38,394,730	515,405
Biomedical Research and Research Training	93.850	Cornell University	1R25GM14207001	88,519	-
Biomedical Research and Research Training	93.850	Florida International University	5R01GM13424703	20,822	-
Biomedical Research and Research Training	93.850	Icahn School Of Medicine At Mount Sinai	7R01GM14344002	62,196	-
Biomedical Research and Research Training	93.850	Northeastern University	R01GM121612	24,505	-
Biomedical Research and Research Training	93.850	Protein Metrics Inc	2R42GM12113302	(316)	-
Biomedical Research and Research Training	93.850	Saint Louis University	1R01GM134081	70,192	-
Biomedical Research and Research Training	93.850	University Of Alabama Birmingham	5R25GM13051704	131,171	-
Biomedical Research and Research Training	93.850	University Of Florida	5R01GM13904603	204,820	-
Biomedical Research and Research Training	93.850	University Of Texas	5R01GM11423708	84,516	-
Biomedical Research and Research Training	93.850	Vanderbilt University	5R01GM11661607	3,901	-
Child Health and Human Development Extramural Research	93.865			21,164,201	4,818,581
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD07281509	29,695	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09113005	45,120	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09244405	165,161	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Of Philadelphia (The)	1R01HD109963	287,488	-
Child Health and Human Development Extramural Research	93.865	Johns Hopkins University	5R01HD09769204	20,659	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	R01HD113188-01	65,903	-
Child Health and Human Development Extramural Research	93.865	Medical College Of Wisconsin	5R01HD10460702	13,685	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134704	1,366	-
Child Health and Human Development Extramural Research	93.865	Neurologists	4R44HD105579-02	173,317	-
Child Health and Human Development Extramural Research	93.865	Northwestern University	5K12HD07394510	(304)	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	U24HD100982	3,099	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	U54HD100982	219,337	-
Child Health and Human Development Extramural Research	93.865	Rector & Visitors Of The University Of Virginia	1R01HD110568-01A1	34,083	-
Child Health and Human Development Extramural Research	93.865	Rector & Visitors Of The University Of Virginia	5R01HD072071	162,668	-
Child Health and Human Development Extramural Research	93.865	Regents Of The University Of Colorado	5R01HD09799004	68,102	-
Child Health and Human Development Extramural Research	93.865	Regents Of The University Of Michigan	1R01HD109251-01A1	107,039	-
Child Health and Human Development Extramural Research	93.865	Seattle Children's Hospital, Research and Foundation	5R01HD102239-03	39,056	-
Child Health and Human Development Extramural Research	93.865	St. Louis College of Pharmacy	3R33HD09974805S1	53,053	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Of Philadelphia (The)	5R01HD10152804	46,215	-
Child Health and Human Development Extramural Research	93.865	Trustees Of Columbia University In the City Of New York	1R01HD112241-01A1	7,107	-
Child Health and Human Development Extramural Research	93.865	University at Buffalo	5R0101HD10481402	9,504	-
Child Health and Human Development Extramural Research	93.865	University Of Alabama Birmingham	1R01HD11299401	17,216	-
Child Health and Human Development Extramural Research	93.865	University Of Massachusetts Medical School	7R01HD09506005	11,485	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	2R01HD055741	420,612	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	5R01HD10390203	27,929	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh School of Medicine	1R25HD109110-01	9,418	-
Child Health and Human Development Extramural Research	93.865	University of Texas Southwestern	5P01HD08438707	495,792	220,802
Child Health and Human Development Extramural Research	93.865	University of Washington	5R01HD10157802	114,853	-
Child Health and Human Development Extramural Research	93.865	Virginia Polytechnic Institute And State University	5P2CHD10191204	18,986	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	1R01HD10821001	54,075	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	5R01HD10585502	97,592	-
Child Health and Human Development Extramural Research	93.865	Yale University	5R01HD106326-02	3,577	-
Aging Research	93.866			109,365,749	22,509,857
COVID-Aging Research	93.866			1,622,812	555,311
Aging Research	93.866	Active Life Scientific	R44AG071034	116,222	-
Aging Research	93.866	Baylor College of Medicine	5P01AG06660603	345,853	-
Aging Research	93.866	Baylor University	5R01AG06529002	67,997	-
Aging Research	93.866	customized learning Exercises for Aural Rehabilitation, LLC	1R43AG06507501A1	(452)	-
Aging Research	93.866	Duke University	1U19AG06518801	100,833	-
Aging Research	93.866	George Washington University	1U19AG078558-01	310,664	-
Aging Research	93.866	Harvard School of Public Health	5R01AG06093503	99,194	-
Aging Research	93.866	Hebrew Rehabilitation Center	5R33AG07174402	14,187	-
Aging Research	93.866	Indiana University	5U01AG05719504	1,418	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Listing Number	Pass Through Entity			
Aging Research	93.866	Indiana University	5U01AG05719505	253,505	-
Aging Research	93.866	Johns Hopkins University	1RF1AG05986001	449,687	-
Aging Research	93.866	Johns Hopkins University	5R01AG04028209	3,428	-
Aging Research	93.866	Mayo Clinic	1U19AG06970101	264,458	-
Aging Research	93.866	Mayo Clinic	1U19AG07487901A1	102,684	-
Aging Research	93.866	Mayo Clinic	3U19AG06391102S1	365,715	-
Aging Research	93.866	Mayo Clinic	5K23AG06402904	5,697	-
Aging Research	93.866	Mayo Clinic	5R01AG075802-03	23,703	-
Aging Research	93.866	Mayo Clinic	5U19AG06391103	183,398	-
Aging Research	93.866	Mayo Clinic	5U19AG06970102	674,407	-
Aging Research	93.866	Mayo Clinic	5U19AG06970103	477,201	-
Aging Research	93.866	Mayo Clinic	WUB-284424/PO #69081362	79,739	-
Aging Research	93.866	Medical College Of Wisconsin	1R01AG07773201	431,296	-
Aging Research	93.866	Northern California Institute For Research And Education	2U19AG02490416	629,578	-
Aging Research	93.866	Northwestern University	5U2CA0604260404S1	(12,227)	-
Aging Research	93.866	Ohio State University	R01AG056919A	(3,347)	-
Aging Research	93.866	Parabon Nanolabs Inc	2R44AG06207202A1	76,170	-
Aging Research	93.866	Pelagos Pharmaceuticals Inc	1R41AG07977801A1	121,219	-
Aging Research	93.866	Pennsylvania State University	5U2CAG06040805	32,787	-
Aging Research	93.866	Rector & Visitors Of The University Of Virginia	5R01AG06704802	103,654	-
Aging Research	93.866	Regenerative Research Foundation	1U1AG072464	506,199	-
Aging Research	93.866	Regents Of The University Of California	1RF1AG05900901	129,083	-
Aging Research	93.866	Regents Of The University Of Michigan	1R01AG07401201	99,614	1,372
Aging Research	93.866	Regents Of The University Of Michigan	5U24AG06518204	34,690	-
Aging Research	93.866	Rutgers The State University Of NJ	7R01AG076774-02	7,580	-
Aging Research	93.866	The Brigham And Women's Hospital Inc	5RF1AG07956002	58,354	-
Aging Research	93.866	The Jackson Laboratory	5R01AG07401202	3,629	1,216
Aging Research	93.866	The Regents of the University of California	5R01AG06114604	11,510	-
Aging Research	93.866	Trustees Of Columbia University In the City Of New York	5U24UA05627007	100,086	-
Aging Research	93.866	Trustees Of Columbia University In the City Of New York	5U24UA05627004	(1,988)	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	1R01AG06857701	23,268	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	1R01AG06993601A1	100,725	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5P01AG03186215	2,790	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5R01AG05443503	(718)	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	7RF1AG06719402	48,337	-
Aging Research	93.866	Tufts University	5R01AG07171702	265,185	-
Aging Research	93.866	University Of Alabama Birmingham	1R01AG06839501A1	(1,232)	-
Aging Research	93.866	University Of Alabama Birmingham	1R01AG081228-01	53,001	-
Aging Research	93.866	University Of Alabama Birmingham	5R01AG06839503	25,105	-
Aging Research	93.866	University Of California Berkeley	1R01AG07895801	213,306	-
Aging Research	93.866	University of California, San Francisco	1R01AG080460-01	21,443	-
Aging Research	93.866	University of California, San Francisco	1R01AG078457-01A1	6,443	-
Aging Research	93.866	University of California, San Francisco	5P30AG06242205	20,011	-
Aging Research	93.866	University of California, San Francisco	5R01AG06235905	22,228	-
Aging Research	93.866	University Of Florida	1RF1AG077160-01A1	145,036	-
Aging Research	93.866	University Of Florida	7RF1AG060769-07	54,113	-
Aging Research	93.866	University Of Florida	R37AG033906	48,208	-
Aging Research	93.866	University Of Illinois Chicago	5R01AG07654102	143,361	-
Aging Research	93.866	University Of Kentucky	5R01AG03865109	16,797	-
Aging Research	93.866	University of Melbourne	5R01AG05867604	510,778	-
Aging Research	93.866	University Of Miami	5R01AG06461404	112,620	-
Aging Research	93.866	University Of North Texas Health Science Center	1U19AG078109-01	59,444	-
Aging Research	93.866	University Of North Texas Health Science Center	5U19AG078109-02	302,543	-
Aging Research	93.866	University Of Pittsburgh	1R01AG06487701A1	909,926	-
Aging Research	93.866	University Of Pittsburgh	1U19AG06805401	(1,380)	-
Aging Research	93.866	University Of Pittsburgh	5R01AG06049905	44,986	-
Aging Research	93.866	University Of Pittsburgh	5U19AG06805403	710,651	-
Aging Research	93.866	University Of Pittsburgh	5U19AG06805403S1	4,135	-
Aging Research	93.866	University Of Pittsburgh	5U19AG06805404	321,023	-
Aging Research	93.866	University of Pittsburgh School of Medicine	1R01AG07326701	915,231	-
Aging Research	93.866	University of Rhode Island	1R01AG079241-01	463,606	-
Aging Research	93.866	University of Rhode Island	5R01AG07924102	178,314	-
Aging Research	93.866	University Of Rochester	5P01AG04720009	63,866	-
Aging Research	93.866	University Of Southern California	1R01AG05379801A1	42,001	-
Aging Research	93.866	University Of Southern California	1R01AG06184801	6,617	-
Aging Research	93.866	University Of Southern California	1R01AG06368901	199,674	-
Aging Research	93.866	University Of Southern California	1R61AG06654301	44,121	-
Aging Research	93.866	University Of Southern California	2P01AG05235006	117,938	-
Aging Research	93.866	University Of Southern California	5P01AG05235005	(1,530)	-
Aging Research	93.866	University Of Southern California	5P01AG05235007	293,199	-
Aging Research	93.866	University Of Southern California	5R01AG05379803	26,373	-
Aging Research	93.866	University Of Southern California	5R01AG05379804	2,784	-
Aging Research	93.866	University Of Southern California	5R01AG05379805	1,742	-
Aging Research	93.866	University Of Southern California	5R01AG05402902	41,245	-
Aging Research	93.866	University Of Southern California	5R21AG08041402	19,838	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance		Pass-through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Listing Number	Pass Through Entity				
Aging Research	93.866	University Of Southern California	5R61AG06654302	10,545	-	-
Aging Research	93.866	University Of Southern California	5U19AG02490417	60,028	-	-
Aging Research	93.866	University Of Southern California	5U24AG05743704	134,963	-	-
Aging Research	93.866	University Of Texas Health Science Center At San Antonio	5R01AG05789604	15,402	-	-
Aging Research	93.866	University of Washington	1U24AG07212201	(23)	-	-
Aging Research	93.866	University of Washington	3U24AG07212201S1	92,607	-	-
Aging Research	93.866	University of Washington	5R01AG06375902	14,675	-	-
Aging Research	93.866	University of Washington	5U24AG07212202	20,776	-	-
Aging Research	93.866	University Of Wisconsin	5R01AG07002802	268,017	-	-
Aging Research	93.866	University Of Wisconsin	5R01AG07088302	40,153	-	-
Aging Research	93.866	Van Andel Research Institute	1R01AG08356801	37,819	-	-
Aging Research	93.866	Vanderbilt University Medical Center	1R01AG07343901	248,960	-	-
Aging Research	93.866	Vanderbilt University Medical Center	5U24AG07485502	541,396	-	-
Aging Research	93.866	Vivid Genomics Inc	1R43AG07610601A1	311	-	-
Aging Research	93.866	Wake Forest University	1R01AG078153-01	11,862	-	-
Aging Research	93.866	Wake Forest University	5R01AG078153-02	124,264	-	-
Aging Research	93.866	WNT Scientific LLC	1R41AG080953-01A1	146,005	-	-
Aging Research	93.866	Yale University	5R01AG06591703	236,113	-	-
Aging Research	93.866	Yale University	5R01AG073969-02	182,956	-	-
Vision Research	93.867			9,117,483		699,974
Vision Research	93.867	Banner Alzheimer's Institute	1RF1AG073424	12,157	-	-
Vision Research	93.867	Children's Hospital Corporation	1R01EY035684-01	114,934	-	-
Vision Research	93.867	Jaeb Center for Health Research Foundation Inc	U10EY11751	4,306	-	-
Vision Research	93.867	Johns Hopkins University	5UG1EY02809103	45,662	-	-
Vision Research	93.867	Legacy Emanuel Hospital & Health Center	R01EY034554	29,012	-	-
Vision Research	93.867	University Of California Irvine	1R01EY03513701	163,035	-	-
Vision Research	93.867	University Of Iowa	1R01EY035266-01	27,566	-	-
Vision Research	93.867	University of Massachusetts Medical School	5R01EY02860203	30	-	-
Vision Research	93.867	University of Missouri System	1R21EY02910601A1	(14,937)	-	-
Vision Research	93.867	University of Missouri System	2R01EY027824-06	53,067	-	-
Vision Research	93.867	West Virginia University	5UG1EY03165403	20,822	-	-
Medical Library Assistance	93.870			440,101		89,631
Medical Library Assistance	93.870	University of California, San Francisco	5R01LM01377804	110,278	-	-
Global Health Research and Research Training	93.080			1,784,243		798,450
Global Health Research and Research Training	93.080	Centre for Infectious Disease Research in Zambia	1D71TW01183702	3,290	-	-
Global Health Research and Research Training	93.080	Northwestern University	5D43TW01197603	5,681	-	-
Global Health Research and Research Training	93.080	University Of North Carolina Chapel Hill	2D43TW009340-11	22,564	-	-
National Center for Advancing Translational Sciences (NCATS)	93.RD	Harvard University	75N95023C00008	36,826	-	-
COVID-National Center for Advancing Translational Sciences (NCATS)	93.RD	Regenstrief Institute	75N95021D00028	287,197	-	-
			GS-OOF-01OCA/ HHSN261201700003B/			
National Cancer Institute (NCI)	93.RD	ICF Incorporated, LLC	75N91022F00002/TO9	145,497	-	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91019D00024	46,205	-	-
COVID-National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91019D00024	354,114	-	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91020F00030	1,254	-	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N9120F00003	315,967	-	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	HHSN261201500003I	78,901	-	-
National Cancer Institute (NCI)	93.RD	Medical Science & Computing	75N98020D00086/75N98020Fo	4,002	-	-
National Cancer Institute (NCI)	93.RD	Medical Science & Computing	75N98020F00014	755	-	-
National Cancer Institute (NCI)	93.RD	Oregon Health & Science University	HHSN26120622012C	13,804	-	-
National Cancer Institute (NCI)	93.RD	Tetralmaging, LLC	75N91022C00055	29,387	-	-
COVID-National Cancer Institute (NCI)	93.RD	Westat	10T2HL16161401	1,140,995	-	45,673
COVID-National Cancer Institute (NCI)	93.RD	Westat	50T2HL16161402	1,187,479	-	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD			47,163	-	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	Duke University	10T2HL156812-01	37,373	-	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	Emmes Company	HHSN2682011400002I	57,259	-	-
COVID-National Heart, Lung and Blood Institute (NHLBI)	93.RD	L3 Healthcare	75N92021D00008	2,306	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			2,251,083		451,315
COVID-National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Fred Hutchinson Cancer Center	0001118806	63,499	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93021C00014	1,684,600	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93019C00051	569,871	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Institute for Clinical Research	75N91019D00024	1,632	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	75N93021R00009	28,528	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	75N93022C00035	457,098	-	-
COVID-National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	75N93022C00035	57,895	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	HHSN272201700060C	(305)	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Seattle Children's Research Institute	75N93022C00036	49,156	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	St. Jude Children's Research Institute	75N93021C00016	649,695	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University Of Alabama Birmingham	HHSN272201600017C	5,463	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University Of Alabama Birmingham	HHSN272201600018C	43,050	-	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University Of Maryland College Park	75N93023C0046	46,108	-	-
National Institute on Drug Abuse (NIDA)	93.RD	Rutgers University	75N95023D0009	364,396	-	-
National Institutes of Health (NIH)	93.RD	Duke University	HHSN275201000003I	4,194	-	-
National Institutes of Health (NIH)	93.RD	RTI International	OT3 HL147798-01	87,584	-	-
National Institutes of Health (NIH)	93.RD	Vivent	RWB_VIVENTTOWU_FY20-21	139,347	-	-
National Institutes of Health (NIH)	93.RD	Westat	HHSN261201600007I	14,760	-	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Office of the Assistant Secretary for Planning and Evaluation					
Policy Research and Evaluation Grants	93.239	University Of Wisconsin	1H79AE000058-02	776	-
Office on Women's Health					
COVID-Advancing System Improvements for Key Issues in Women's Health	93.088			430,671	-
Substance Abuse and Mental Health Services Administration					
Projects of Regional and National Significance	93.243			42,537	-
Projects of Regional and National Significance	93.243	University of Missouri, St. Louis	SMo85050	16,264	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				<u>763,709,268</u>	<u>93,980,877</u>
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION					
National Aeronautics and Space Administration					
Science	43.001			11,401,539	2,076,696
Science	43.001	Colorado School of Mines	8oNSSC22K1105	39,504	-
Science	43.001	Johns Hopkins University	8oNSSC24M0004	24,106	-
Science	43.001	Rensselaer Polytechnic Institute	8oNSSC19M0069	81,510	-
Science	43.001	Smithsonian Institution	G0324018B	9,969	-
Science	43.001	Smithsonian Institution	G03-24078B	28,158	-
Science	43.001	Smithsonian Institution	G0122033B	(8,982)	-
Science	43.001	Smithsonian Institution	NAS8-03060	6,719	-
Science	43.001	University of Chicago	8oNSSC21M0116	238,375	-
Science	43.001	University of Georgia	8oNSSC22K0132	16,003	-
Science	43.001	University of New Mexico	8oNSSC19K0958	85,688	-
Science	43.001			3,359	-
Space Operations	43.007			21,387	-
Education	43.008	University of Missouri System	8oNSSC20M0100	64,708	-
Space Technology	43.012			739,248	375,046
NASA	43.RD	Arizona State University	NNG07EK00C	134,494	-
NASA	43.RD	Jet Propulsion Laboratory	1658021	(157)	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710630	20,870	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710805	36,116	-
NASA	43.RD	Johns Hopkins University	8oMSFC20D0004	110,851	-
NASA	43.RD	Southwest Research Institute	NASW-02008	28,624	-
NASA	43.RD	Southwest Research Institute	NNN12AA01C	58,992	-
NASA	43.RD	University of Texas Austin	NNM16AA26C	4,189	-
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION				<u>13,145,270</u>	<u>2,451,742</u>
NATIONAL SCIENCE FOUNDATION					
National Science Foundation					
National Science Foundation	47.RD			318,512	-
Engineering Grants	47.041			3,087,385	250,396
Engineering Grants	47.041	OsciFlex LLC	2132561	32,176	-
Engineering Grants	47.041	Renerva LLC	2151582	86,567	-
Engineering Grants	47.041	Trustees Of The University Of Pennsylvania	CMMI-1548571	1,038,213	-
Engineering Grants	47.041	University of Central Florida	1908167	(680)	-
Engineering Grants	47.041	University of Illinois at Urbana-Champaign	1900277	68,989	-
Engineering Grants	47.041	University of Pittsburgh	CBET-2326096	8,504	-
Mathematic and Physical Sciences	47.049			4,770,098	120,535
Mathematic and Physical Sciences	47.049	Barnard College	1828168	(1,809)	-
Mathematic and Physical Sciences	47.049	Harvard University	2127882	310,618	-
Mathematic and Physical Sciences	47.049	Missouri University of Science and Technology	CHE-2155175	24,498	-
Mathematic and Physical Sciences	47.049	Smithsonian Institution	SV121007	7,000	-
Mathematic and Physical Sciences	47.049	Southern Illinois University Edwardsville	2328837	27,245	-
Mathematic and Physical Sciences	47.049	University of Nevada at Reno	2326801	50,494	-
Geosciences	47.050			1,018,490	-
Computer and Information Science and Engineering	47.070			4,182,584	97,752
Computer and Information Science and Engineering	47.070	Colorado School of Mines	2118201	93,964	-
Computer and Information Science and Engineering	47.070	University Of California Berkeley	1640899	(2,719)	-
Computer and Information Science and Engineering	47.070	University of Illinois at Urbana-Champaign	2103680	25,241	-
Computer and Information Science and Engineering	47.070	University of Utah	2002158	269,929	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS182688	51,019	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS1827940	47,330	-
Computer and Information Science and Engineering	47.070	West Virginia University	IIS-2114644	(380)	-
Biological Sciences	47.074			5,058,832	515,955
Biological Sciences	47.074	American University	1948181	35,252	-
Biological Sciences	47.074	Baylor College of Medicine	2131806	62,868	-
Biological Sciences	47.074	Baylor College of Medicine	DBI-2021795	223,306	-
Biological Sciences	47.074	Carnegie Institution of Washington	DBI-2213983	917	-
Biological Sciences	47.074	Michigan State University	2243230	63,709	-
Biological Sciences	47.074	Michigan State University	2419923	68,369	-
Biological Sciences	47.074	University of Wisconsin, Madison	1840687	73,335	-
Social, Behavioral, and Economic Sciences	47.075			1,208,835	-
Social, Behavioral, and Economic Sciences	47.075	Boston University	SES2120115	21,179	-
Social, Behavioral, and Economic Sciences	47.075	Rice University	2243593	24,179	-
Education and Human Resources	47.076			2,010,762	-
Education and Human Resources	47.076	Baylor University	1920730	80,872	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Education and Human Resources	47.076	Jackson State University	2000135	1,088	-
Education and Human Resources	47.076	University of Alabama	1915544	55,295	-
Polar Programs	47.078			73,303	-
Office of International Science and Engineering	47.079			90,008	29,497
Office of International Science and Engineering	47.079	CFDF Global	202304-70821	20,999	-
Office of International Science and Engineering	47.079	University of Wisconsin	OISE-20-66590-1	3,075	-
Office of Integrative Activities	47.083			895,270	-
NSF Technology, Innovation, and Partnerships	47.084			768,892	99,200
NSF Technology, Innovation, and Partnerships	47.084	Massachusetts Institute Of Technology	TI-2229704	3,539	-
TOTAL NATIONAL SCIENCE FOUNDATION				<u>26,357,152</u>	<u>1,112,435</u>
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Agency for International Development					
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Mississippi State University	7200AA18CA00030	47,479	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	National Academy of Sciences	AID263A1500002	(10,136)	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	University Of Georgia	7200AA18CA00003	168,045	25,000
Agency for International Development	98.RD	Mississippi State University	10390031245502E	16,156	-
Agency for International Development	98.RD	Mississippi State University	7200AA18CA00030	345	-
Agency for International Development	98.RD	Tufts University	7200AA18CA00030	100,494	43,734
DEPARTMENT OF AGRICULTURE					
National Institute of Food and Agriculture					
Biotechnology Risk Assessment Research	10.219			251,614	-
Agriculture and Food Research Initiative (AFRI)	10.310			55,234	41,986
Agriculture and Food Research Initiative (AFRI)	10.310	Washington State University	2022-68016-37113	80,871	-
DEPARTMENT OF COMMERCE					
Climate and Atmospheric Research	11.431			49,250	-
Weather and Air Quality Research	11.459	University of Wisconsin	NA23OAR4590411	8,218	-
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT					
Department of Housing and Urban Development					
Homeland Security Research, Development, Testing, Evaluation and Demonstration of Technologies Related to Countering Weapons of Mass Destruction	97.077	City of St. Louis	19DNFRV000010201	(1,159)	-
DEPARTMENT OF JUSTICE					
Crime Victim Assistance/Discretionary Grants	16.582			105,072	54,716
Public Safety Partnership and Community Policing Grants	16.710	Center for Naval Analyses	15JCOPS21GK02399SPPS	121,686	-
Improving the Investigation and Prosecution of Child Abuse and the Regional and Local Children's Advocacy Centers	16.758			34,364	924
DEPARTMENT OF STATE					
International Programs to Combat Human Trafficking	19.019			601,494	304,498
Overseas Refugee Assistance Programs for Strategic Global Priorities	19.522			1,734	-
Bureau of Near Eastern Affairs	19.600	Johns Hopkins University	SMEAAC21CA3040	79,681	-
DEPARTMENT OF THE INTERIOR					
Assistance to State Water Resources Research Institutes	15.805	University of Missouri System	G16AP00066	(1,431)	-
DEPARTMENT OF TRANSPORTATION					
Federal Highway Administration					
National Highway Traffic Safety Administration	20.RD	Wake Forest University	693JJ922F00202N	3,739	-
National Highway Traffic Safety Administration	20.RD	Wake Forest University	DTNH2217D00070	(413)	-
DEPARTMENT OF VETERANS AFFAIRS					
Department of Veterans Affairs	64.RD			56,450	-
Department of Veterans Affairs	64.RD	University Of North Carolina Chapel Hill	36C24120D0021	4,004	-
ENVIRONMENTAL PROTECTION AGENCY					
Office of Research and Development					
Science to Achieve Results (STAR) Research Program	66.509			160,586	-
UNITED STATES INSTITUTE OF PEACE					
United States Institute of Peace	91.RD			42,704	-
Total Research & Development Cluster				<u>841,998,351</u>	<u>102,807,820</u>
Other Sponsored Programs					
DEPARTMENT OF DEFENSE					
U.S. Army Medical Command					
Military Medical Research and Development	12.U01	Synedgen Inc	(MTEC)-2021-476	53,230	-
Military Medical Research and Development	12.U02	University of Pittsburgh School of Medicine	W81XWJ16D0024W81XWH18Fo4	35,074	-
TOTAL DEPARTMENT OF DEFENSE				<u>88,304</u>	<u>-</u>
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Strategic Preparedness & Response					
Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion	93.078			29,738	-
Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion	93.078			3,526	-
Centers for Disease Control					
Centers for Disease Control and Prevention	93.U01			7,548	-
Centers for Disease Control and Prevention	93.U02			141,933	-
Centers for Disease Control and Prevention	93.U03			5,698	-
Centers for Disease Control and Prevention	93.U04			650,394	-
Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.073	Tourette Association of America, Inc.	NU38DD00001	34,568	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Colorectal Cancer Screening Program	93.800	University of Missouri	5NU58DP0067650300	18,363	-
HIV Prevention Activities Non-Governmental Organization Based	93.939	Vivent Health	1NU62PS924648-01-00	725	-
HIV Prevention Activities Non-Governmental Organization Based	93.939	Vivent Health	5NU62PS92464803-00	84,508	-
HIV Prevention Activities_Health Department Based	93.940	Missouri Department of Health and Human Services	DH200047810	12,486	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	11107110010	27,570	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	11667114011	25,205	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	6NU62PS92457705	31,729	-
TOTAL HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED				96,990	-
Preventive Health Services_Sexually Transmitted Diseases Control Grants	93.977			215,455	-
Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems	93.988	American Academy of Pediatrics	1NU58DP007422-01-00	30,159	-
Autism and Other Developmental Disabilities, Surveillance, Research, and Prevention	93.998			527,759	-
Food and Drug Administration					
Food and Drug Administration	93.U05	American College of Medical Toxicology Inc	75F40122D00028	38,404	-
Food and Drug Administration	93.U06	Children's Hospital Of Philadelphia (The)	75F40120C00135	11,203	-
Health Resources and Services Administration					
Health Resources and Services Administration	93.U07	Health Research Inc	HRS15-0899-01	18,965	-
Health Resources and Services Administration	93.U08	St Clair County	Unknown	18,735	-
Health Resources and Services Administration	93.U09	Vivent Health	CS232774001	55,749	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	2U03MC22684-13-00	135,950	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	5U03MC22684-11-00	51,744	-
Emergency Medical Services for Children	93.127	University of Missouri System	2H33MC31623-06-00	8,369	-
TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN				196,063	-
Sickle Cell Treatment Demonstration Program	93.365			1,120,753	516,132
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	21-84	(987)	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	23-44	667,445	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	23-45	44,504	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	23-46	60,416	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	23-47	17,644	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	23-69	9,438	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	24-73	353,947	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	24-74	23,365	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	24-75	35,101	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	24-76	10,421	-
TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS				1,221,294	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	05780063H-4-1	81,116	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	DH200048389	120,166	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	DH230051646	501,235	105,100
TOTAL HIV CARE FORMULA GRANTS				702,517	105,100
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			531,904	57,763
Special Projects of National Significance	93.928			52,702	38,692
Office of Assistant Secretary for Health					
Family Planning Services	93.217	Missouri Family Health Council	FPHPA006561	229,390	-
Office of the Secretary of Health and Human Services					
COVID-Biomedical Advanced Research and Development Authority (BARDA)	93.U10	Duke University	HHSO100201400002I	(64)	-
Substance Abuse and Mental Health Services Administration					
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243			177,849	-
Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243	Vision for Children at Risk	VCRSTLPL	114,158	-
Congressional Directives	93.493	BJC Health System	6H79FG000822-01M004	20,070	-
State Targeted Response to the Opioid Crisis Grants	93.788	University of Missouri, St. Louis	1H79TIO85748-01	228,602	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				6,585,658	717,687
DEPARTMENT OF JUSTICE					
Office of Juvenile Justice and Delinquency Prevention					
Second Chance Act Reentry Initiative	16.812	Soulfisher Ministry	15BJA-22-GG-01773-SCAX	64,915	-
Second Chance Act Reentry Initiative	16.812	Soulfisher Ministry	15RBJA-22-GG-04605-SCAX	134,617	-
				199,532	-
DEPARTMENT OF HOMELAND SECURITY					
Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97.036			1,329,297	-

The accompanying notes are an integral part of this schedule

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2024

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub- Recipients
DEPARTMENT OF STATE					
International Programs to Combat Human Trafficking	19.019	University Of Georgia	SSJITIP22CA0029	113,130	-
AEECA/ESF PD Programs	19.900	American Councils for International Education	SUZ80021CA3148	6,294	-
				<u>119,424</u>	-
DEPARTMENT OF THE TREASURY					
Internal Revenue Service					
Low Income Taxpayer Clinics	21.008			208,736	-
DEPARTMENT OF VETERANS AFFAIRS					
Department of Veterans Affairs	64.RD			11,564	-
NATIONAL ARCHIVES AND RECORDS ADMINISTRATION					
NATIONAL ENDOWMENT FOR THE ARTS					
Promotion of the Arts Grants to Organizations and Individuals	45.024			2,154	-
Total Other Sponsored Programs from Other Federal Agencies				<u>1,870,707</u>	-
Total Other Sponsored Programs				<u>8,544,669</u>	<u>717,687</u>
Student Financial Assistance Cluster					
DEPARTMENT OF EDUCATION					
Federal Supplemental Educational Opportunity Grant	84.007			1,516,651	-
Federal Work-Study Program	84.033			1,945,088	-
Federal Pell Grant Program	84.063			8,365,352	-
Teacher Education Assistance for College and Higher Education Grants	84.379			124,476	-
Education Stabilization Fund	84.425			9,406	-
Federal Direct Student Loans					
New Loans Issued during 2024	84.268			60,199,706	-
Federal Perkins Loans					
Outstanding Loans as of July 1, 2023	84.038			7,026,348	-
Total Student Financial Assistance Cluster				<u>79,187,027</u>	-
Highway Safety Cluster					
DEPARTMENT OF TRANSPORTATION					
Police Traffic Services	20.600	Missouri Dept of Transportation	23DL02001	39,868	-
Food for Peace Cluster					
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Food for Peace Development Assistance Program (DAP)	98.007	Catholic Relief Services	720BHA21RFA00002	353,039	-
TRIO Cluster					
DEPARTMENT OF EDUCATION					
TRIO - Student Support Services	84.042			350,935	-
Total Federal Award Expenditures				<u>\$ 930,473,889</u>	<u>\$ 103,525,507</u>

The accompanying notes are an integral part of this schedule

Washington University
Notes to Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2024

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) summarizes the expenditures of Washington University (the “university”) under programs of the Federal Government for the year ended June 30, 2024. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the financial statements. The university includes the amounts in the Schedule in net assets without donor restrictions of the university’s Consolidated Statement of Activities for the year ended June 30, 2024.

The Schedule is prepared on the accrual basis of accounting. Assistance Listing and pass-through numbers are provided when available. Negative amounts presented as expenditures represent subsequent period adjustments, transfers, or vendor credits. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 26.0% to 55.5%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2024.

3. Federal Student Loan Programs

The following schedule includes the Student Financial Aid (SFA) loan balances outstanding as of June 30, 2024:

Student Financial Aid	Federal Assistance Listing Number	Outstanding Balances
U.S. Department of Education		
Federal Perkins Loan Program	84.038	4,589,887

Reports on Compliance and on Internal Controls



**Report of Independent Auditors on Internal Control Over Financial
Reporting and on Compliance and Other Matters Based on an Audit of
Financial Statements Performed in Accordance with *Government Auditing
Standards***

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statement of financial position as of June 30, 2024, and the related consolidated statements of activities and of cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated September 27, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Washington, District of Columbia

September 27, 2024



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Trustees of Washington University

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Washington University's (the "University") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2024. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform



Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 11 "Gramm-Leach-Bliley Act-Student Information Security." This section includes two suggested audit procedures with respect to verification that the institution (1) designated a Qualified Individual responsible for implementing and monitoring the institution's information security program, and (2) has a written information security program that addresses the remaining six required minimum elements that are detailed in the OMB Compliance Supplement, Part Five, Student Financial Assistance Cluster, Special Tests and Provisions, item 11, Gramm-Leach-Bliley Act – Student Information Security. Our procedures in relation to these two items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these two items. Our procedures did not include an analysis of the adequacy or completeness of the minimum required elements of the institution's information security program.

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2024-001, 2024-002, and



2024-003. Our opinion on each major federal program is not modified with respect to these matters.

Government Auditing Standards requires the auditor to perform limited procedures on the University's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs and corrective action plan. The University's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Washington, District of Columbia

March 7, 2025

Schedule of Findings and Questioned Costs

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2024

Part I - Summary of Auditor's Results

Financial Statements

Type of auditor's report issued:

Unmodified

Internal control over financial reporting:

Material weakness (es) identified?

_____ Yes X No

Significant deficiency (ies) identified not considered
to be material weaknesses?

_____ Yes X None reported

Noncompliance material to financial statements noted?

_____ Yes X No

Federal Awards

Type of auditor's report issued on compliance for
major programs:

Unmodified

Internal control over major programs:

Material weakness (es) identified?

_____ Yes X No

Significant deficiency (ies) identified not considered
to be material weaknesses?

_____ Yes X None reported

Any audit findings disclosed that are required to be
reported in accordance with Uniform Guidance
Section 200.516(a)?

 X Yes _____ No

Identification of Major Programs:

Assistance Listing Number(s)

Name of Federal Program or Cluster

Various

Research and Development Cluster

Various

Student Financial Aid Cluster

97.036

Disaster Grants - Public Assistance
(Presidentially Declared Disasters)

Dollar threshold used to distinguish between
Type A and Type B programs:

\$3,000,000

Auditee qualified as low-risk auditee?

 X Yes _____ No

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2024

Part II – Financial Statement Findings

There are no financial statement findings to report.

Part III – Federal Award Findings and Questioned Cost

Finding 2024-001: Special Tests and Provisions –Disbursements to or on Behalf of Students, Enrollment Reporting, and Return of Title IV funds

Grantor: Department of Education
Program: Student Financial Assistance Cluster
Assistance Listing#: 84.007, 84.033, 84.063 & 84.268
Title: Federal Supplemental Educational Opportunity Grants, Federal Work-Study Program, Federal Pell Grant Program, Federal Direct Student Loans
Award Year: 07/1/2023 – 06/30/2024
Award Number: N/A

Criteria

34 CFR 668.165 which requires the institution to obtain the student's voluntary consent to participate in electronic transactions.

34 CFR 668.41 which notes an institution annually must distribute to all enrolled students a notice of the availability of the information required to be disclosed under the notification requirements of the Family Educational Rights and Privacy Act of 1974.

34 CFR 668.165 which requires the institution, in advance of disbursement, to provide a general notification to all students receiving Title IV program funds including (1) amount of funds the student can expect to receive from each Federal Student Aid (FSA) program and (2) how and when those funds will be disbursed

34 CFR Section 674.19 which states unless it expects to submit its next updated enrollment report to the Secretary within the next 60 days, an institution must notify the Secretary within 30 days after the date the school discovers that a student has ceased to be enrolled on at least a half-time basis or failed to enroll on at least a half-time basis for the period for which the loan was intended. Student status changes are required to be reported at both the "Campus Level" and "Program-Level" as each have separate record types.

34 CFR 668.21-22 which includes the requirements for determining the amount of Title IV funding to be returned to the Department of Education as well as the required order and timeframe for return of Title IV funds.

Condition

Disbursements to or on behalf of students

- For 21 of 25 students sampled, the University was unable to provide evidence of each student's affirmative consent for electronic communications
- For 25 of 25 students sampled, the University was unable to provide evidence that each student received notification of the availability of the Annual Security Report and Annual Fire Safety Report as required under the Clery Act
- For 1 of 25 students sampled, the University was unable to evidence that they provided the student with their general award notification which includes the amount of funds expected to be received and timing of disbursement

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2024

Enrollment reporting

- For 1 of 25 students sampled, the student's change in enrollment status was not reported to the National Student Loan Data System (NSLDS) within the 60 required timeframe

Return of Title IV funds

- For 1 of 6 students sampled, the University did not complete a return of Title IV funding worksheet to determine whether financial aid funding was required to be returned to the Department of Education

Cause

The University experienced turnover in the Student Financial Aid Office as well as other offices that support the University's ongoing compliance with the Student Financial Assistance regulations. Additionally, the absence of a secondary level of review impacted the University's ability to ensure compliance with federal regulations.

Effect

The University's was unable to demonstrate compliance with certain required federal regulations.

Questioned Costs

There are no questioned costs associated with this finding as the finding primarily relates to required student notifications and reporting. As it specifically relates to the Return of Title IV funds exception, no questioned costs were noted as there were no amounts that were required to be returned to the Department of Education.

Recommendation

Management should cross train individuals within the Student Financial Aid Office as well as other offices that support financial aid administration to ensure the University is able to remain compliant with federal regulations during periods of turnover in personnel. Separately, the University should implement a process for reminders, secondary review, and follow up to ensure reporting obligations are met timely, completely, and accurately.

Management's View and Corrective Action Plan

Please refer to management's views and corrective action plan.

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2024

Finding 2024-002: Reporting - Schedule of Expenditures of Federal Awards

Grantor: National Institute of Health

Program: Research and Development

Assistance Listing#: 93.352

Title: A Washington University Gnotobiotic Research, Education and Transgenic center for modeling genetic and environmental effectors of disease pathogenesis

Award Year: 09/20/2019 – 05/31/2024

Award Number: 1Co6OD02830601

Criteria

2 CFR 200.510 which requires the auditee to prepare a Schedule of Expenditures of Federal Awards (SEFA) for the period covered by the auditee's financial statements that includes the total federal awards expended.

Condition

Expenditures totaling \$2,013,944 related to a construction grant were incurred in prior fiscal years but recorded in the SEFA during the current fiscal year.

Cause

The management of the construction grant activity resided in a department other than Sponsored Projects Accounting. Therefore, the grant was excluded from the normal processes for capturing activity in the SEFA.

Effect

The current year SEFA is overstated by amounts that should have been recorded in the SEFA in prior years.

Questioned Costs

There are no questioned costs as amounts sampled from the expenditures recorded in the current year SEFA were deemed allowable.

Recommendation

Management should enhance its coordination and review procedures for special purpose grants managed outside of Sponsored Projects Accounting to ensure that amounts associated with such grants are completely and accurately reported in the SEFA.

Management's View and Corrective Action Plan

Please refer to management's views and corrective action plan.

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2024

Finding 2024-003: Procurement, Suspension, and Debarment

Grantor: National Institute of Health
Program: Research and Development
Assistance Listing#: 93.395, 93.866
Title: Cancer Treatment Research, Aging Research
Award Year: 03/01/2019-11/30/2023, 02/15/2021-01/31/2026
Award Number: 3UM1CA18670405S1, 5R01AG07094105

Criteria

2 CFR 200, Subpart D which require institutions to:

- Maintain and use documented procedures for procurement transactions under a federal award or subaward, including for acquisition of property or services
- Maintain records sufficient to detail the history of each procurement transaction. These records must include the rationale for the procurement method, contract type selection, contractor selection or rejection, and the basis for the contract price

2 CFR 200.214 which restricts making federal awards, subawards, and contracts with certain parties that are debarred, suspended, or otherwise excluded from receiving or participating in federal awards.

Condition

- For 2 of 25 procurements sampled, the University documented both supplier justification and the purchase order after receipt of an invoice from the vendor
- For 1 of 25 procurements sampled, the University did not maintain evidence of their price/cost analysis as required when the procurement exceeds the simplified acquisition threshold of \$250,000
- For 1 of 25 samples selected for suspension and debarment, the University performed the suspension/debarment screen after the date and payment of the vendor invoice

Cause

For vendors that existed in the legacy accounting system, the University has not consistently documented vendor screening results. Additionally, procurement decisions/conclusions were not consistently documented prior to executing transactions with vendors.

Effect

There is a risk that the University could enter into transactions with vendors that are suspended/debarred. Separately, failure to document procurement decisions in a timely manner could impact the University's ability to demonstrate compliance with federal regulations and the University's procurement policies.

Questioned Costs

There are no questioned costs as the vendor selected was not suspended or debarred and procurement transactions were deemed allowable.

Recommendation

Management should enhance its existing processes to ensure all decisions and conclusions supporting procurements are made in a timely manner and completely documented in the procurement files prior to entering into transactions with vendors. The University should also ensure that all required suspension and debarment checks are performed, and documentation is maintained in advance of transacting with vendors.

Management's View and Corrective Action Plan

Please refer to management's views and corrective action plan.

Summary of Status of Prior Audit Findings

Washington University

Summary of Status of Prior Audit Findings

Year Ended June 30, 2024

Part IV – Federal Award Findings

Finding 2023-001 Allowable Costs/Cost Principles – Cost Transfers

During fiscal year 2023, 44 cost transfers, which included cost transfers related to payroll and non-payroll costs, were selected for testing. 25 selections from the Research and Development cluster totaled \$368,956, and 19 selections from the Sickle Cell Treatment Demonstration Program cluster totaled \$28,628. Two of the 25 Research and Development cluster cost transfers, totaling \$24,438, were not completed within 90 days following the discovery of error occurrence as required by the National Institute of Health's (NIH) Grants policy. One of the 19 Sickle Cell Treatment Demonstration Program cluster cost transfers, totaling \$4,951, was not completed within 90 days following the error occurrence as required by the Department of Health and Human Services (DHHS) Grants policy.

Status and Action Taken:

Management has implemented various appropriate corrective actions. The University's Cost Transfer for Sponsored Projects policy was updated during fiscal year 2024 to include more specific language regarding the timing requirements for awards from NIH, DHHS, and other sponsoring agencies (see below). In addition, management continues to provide ongoing communication to the research community about the importance of adhering to cost transfer deadlines through its various communication channels, including, but not limited to, Research Administrator meetings and the Research News emails.

Update to Cost Transfer for Sponsored Projects policy:

Faculty and staff are responsible for ensuring that Cost Transfers are processed in a timely manner. Cost Transfers should be prepared and submitted within 90 days from the date of discovery (per National Institutes of Health Grants Policy Statement section 7.5). In cases when the sponsor's (federal or non-federal) terms and conditions relating to the timing of Cost Transfers are stricter than this policy, the sponsor's terms and conditions are applicable and supersede this policy. Note: The Department of Health and Human Services agencies (e.g., funding from HRSA, CDC, AHRQ...) grants policy requires cost transfers to be made promptly after the error occurs but no later than 90 days following occurrence unless a longer period is approved in advance by the GMO.

Management's Views and Corrective Action Plan

Washington University
EIN# 43-0653611
Management's Views and Corrective Action Plan
For the Year Ended June 30, 2024



Accountant's Finding 2024-001: Special Tests and Provisions –Disbursements to or on Behalf of Students, Enrollment Reporting, and Return of Title IV funds

Management concurs with the finding and is implementing the following corrective actions:

Disbursements to or on behalf of students

- Student Financial Services (SFS) has updated the Financial Assistance Terms and Conditions, which is required to be certified annually by all students receiving aid, to include consent to receive electronic communications.
- In accordance with the requirements of the Clery Act, the Annual Campus Security and Fire Safety Report (ASFSR) is posted and available on the WU Police Department website. The WU Police Department has partnered with the Office of the Executive Vice Chancellor for Administration and the Office of Information Technology to establish responsibilities and timelines that will ensure students, faculty, and staff are notified, prior to October 1 of each year, that the most recent ASFSR is available on the website. Additionally, the university's Internal Audit Department will follow-up quarterly to ensure implementation of this action plan.
- Student award notifications are delivered to students electronically through an automated process that identifies aid awarded but not yet disbursed. For the rare occasions that a student may have aid awarded and disbursed in the same day, therefore bypassing the overnight award notification process, SFS has implemented the review of a pre-disbursement daily report to identify students who have an aid offer but were not provided an aid notification.

Enrollment reporting

- The Office of the Registrar has updated its procedures to include off-schedule enrollment submissions through NSLDS. On the completion of the National Student Clearinghouse graduate-only file and corrections, an ad-hoc enrollment submission request will be completed.

Return of Title IV funds

- To ensure compliance with its internal policy, SFS has updated procedures to complete a formal R2T4 calculation within the student aid system on all withdrawing Title IV students. To monitor that no students are missed as part of the routine procedures, a new report has been created to identify withdrawn Title IV students. This report will be compared bi-weekly to the student aid system to confirm that R2T4 calculations have been completed.

Additional

- SFS depends on multiple departments across campus to compliantly deliver federal Title IV aid. SFS will develop an annual training plan for campus partners to ensure they have the knowledge and resources to administer federal aid in compliance with federal regulations. SFS has hired an Associate Director of Operations and Training who will develop this training during calendar year 2025. The university's Internal Audit Department will follow-up quarterly to ensure implementation of this action plan.

Completion Date: June 30, 2025

University Contact and Responsible Party: Michael Runiewicz, Assistant Vice Provost & Director of Student Financial Services, (314) 935-5900

Washington University

EIN# 43-0653611

Management's Views and Corrective Action Plan

For the Year Ended June 30, 2024



Finding 2024-002: Reporting - Schedule of Expenditures of Federal Awards

Management concurs with the finding and will ensure that construction grant expenditures are recorded in the financial system in the proper period by documenting appropriate procedures in coordination between Sponsored Projects Accounting office and the Property Accounting Office.

Completion Date: December 31, 2025

University Contact and Responsible Party: Krystina J. Gross, Associate Vice Chancellor for Finance and Sponsored Projects, (314) 935-2073

Washington University

EIN# 43-0653611

Management's Views and Corrective Action Plan

For the Year Ended June 30, 2024



Finding 2024-003: Procurement, Suspension, and Debarment

Management will review and clarify our procurement policies and procedures to ensure alignment with Uniform Guidance. We will clarify what documentation is sufficient to justify a lack of competition for purchases greater than the micro-purchase threshold. We will reinforce the need to document procurement decisions prior to entering into the procurement process and adequately retain the documentation by issuing targeted communication and presenting at various standing research administration staff meetings.

Completion Date: December 31, 2025

University Contact and Responsible Party: Krystina J. Gross, Associate Vice Chancellor for Finance and Sponsored Projects, (314) 935-2073